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a b s t r a c t
Much medical research is observational. The reporting of observational studies is often of insufﬁcient
quality. Poor reporting hampers the assessment of the strengths and weaknesses of a study and the gen-
eralisability of its results. Taking into account empirical evidence and theoretical considerations, a group of
methodologists, researchers, and editors developed the Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) recommendations to improve the quality of reporting of observational
studies. The STROBE Statement consists of a checklist of 22 items, which relate to the title, abstract,
introduction, methods, results and discussion sections of articles. Eighteen items are common to cohort
studies, caseecontrol studies and cross-sectional studies and four are speciﬁc to each of the three study
designs. The STROBE Statement provides guidance to authors about how to improve the reporting of
observational studies and facilitates critical appraisal and interpretation of studies by reviewers, journal
editors and readers. This explanatory and elaboration document is intended to enhance the use, under-
standing, and dissemination of the STROBE Statement. The meaning and rationale for each checklist item
are presented. For each item, one or several published examples and,where possible, references to relevant
empirical studies and methodological literature are provided. Examples of useful ﬂow diagrams are also
included. The STROBE Statement, this document, and the associated Web site (http://www.strobe-
statement.org/) should be helpful resources to improve reporting of observational research.
© 2014 The Authors. Published by Elsevier Ltd on behalf of Surgical Associates Ltd. This is an open access
article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
1. Introduction
Rational health care practices require knowledge about the
aetiology and pathogenesis, diagnosis, prognosis and treatment of
diseases. Randomised trials provide valuable evidence about
treatments and other interventions. However, much of clinical or
public health knowledge comes from observational research [1].
About nine of ten research papers published in clinical speciality
journals describe observational research [2,3].
Abbreviations: CI, conﬁdence interval; RERI, Relative Excess Risk from Interac-
tion; RR, relative risk; STROBE, Strengthening the Reporting of Observational
Studies in Epidemiology.
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1.1. The STROBE Statement
Reporting of observational research is often not detailed and
clear enough to assess the strengths and weaknesses of the
investigation [4,5]. To improve the reporting of observational
research, we developed a checklist of items that should be
addressed: the Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) Statement (Table 1). Items
relate to title, abstract, introduction, methods, results and
discussion sections of articles. The STROBE Statement has
recently been published in several journals [6]. Our aim is to
ensure clear presentation of what was planned, done, and
found in an observational study. We stress that the recom-
mendations are not prescriptions for setting up or conducting
studies, nor do they dictate methodology or mandate a uniform
presentation.
Table 1
The STROBE Statementdchecklist of items that should be addressed in reports of observational studies.
Item
number
Recommendation
Title and Abstract 1 (a) Indicate the study's design with a commonly used term in the title or the abstract
(b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction
Background/rational 2 Explain the scientiﬁc background and rationale for the investigation being reported
Objectives 3 State speciﬁc objectives, including any prespeciﬁed hypotheses
Methods
Study design 4 Present key elements of study design early in the paper
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants 6 (a) Cohort studydGive the eligibility criteria, and the sources and methods of selection of participants. Describe methods
of follow-up
Caseecontrol studydGive the eligibility criteria, and the sources and methods of case ascertainment and control
selection. Give the rationale for the choice of cases and controls
Cross-sectional studydGive the eligibility criteria, and the sources and methods of selection of participants
(b) Cohort studydFor matched studies, give matching criteria and number of exposed and unexposed
Caseecontrol studydFor matched studies, give matching criteria and the number of controls per case
Variables 7 Clearly deﬁne all outcomes, exposures, predictors, potential confounders, and effect modiﬁers. Give diagnostic criteria,
if applicable
Data sources/
measurement
8a For each variable of interest, give sources of data and details of methods of assessment (measurement).
Describe comparability of assessment methods if there is more than one group
Bias 9 Describe any efforts to address potential sources of bias
Study size 10 Explain how the study size was arrived at
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen,
and why
Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding
(b) Describe any methods used to examine subgroups and interactions
(c) Explain how missing data were addressed
(d) Cohort studydIf applicable, explain how loss to follow-up was addressed
Caseecontrol studydIf applicable, explain how matching of cases and controls was addressed
Cross-sectional studydIf applicable, describe analytical methods taking account of sampling strategy
(e) Describe any sensitivity analyses
Results
Participants 13a (a) Report the numbers of individuals at each stage of the studyde.g., numbers potentially eligible, examined for
eligibility, conﬁrmed eligible, included in the study, completing follow-up, and analysed
(b) Give reasons for non-participation at each stage
(c) Consider use of a ﬂow diagram
Descriptive 14a (a) Give characteristics of study participants (e.g., demographic, clinical, social) and information on exposures and
potential data confounders
(b) Indicate the number of participants with missing data for each variable of interest
(c) Cohort studydSummarise follow-up time (e.g., average and total amount)
Outcome data 15a Cohort studydReport numbers of outcome events or summary measures over time
Caseecontrol studydReport numbers in each exposure category, or summary measures of exposure
Cross-sectional studydReport numbers of outcome events or summary measures
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% conﬁdence
interval). Make clear which confounders were adjusted for and why they were included
(b) Report category boundaries when continuous variables were categorized
(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses 17 Report other analyses donede.g., analyses of subgroups and interactions, and sensitivity analyses
Discussion
Key results 18 Summarise key results with reference to study objectives
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction
and magnitude of any potential bias
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results
from similar studies, and other relevant evidence
Generalisability 21 Discuss the generalisability (external validity) of the study results.
Other information
Funding 22 Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on
which the present article is based.
a Give such information separately for cases and controls in caseecontrol studies, and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The
STROBE checklist is best used in conjunction with this article (freely available on theWeb sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine
at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Separate versions of the checklist for cohort, caseecontrol, and cross-sectional studies are
available on the STROBE Web site at http://www.strobe-statement.org/.
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STROBE provides general reporting recommendations for
descriptive observational studies and studies that investigate as-
sociations between exposures and health outcomes. STROBE ad-
dresses the three main types of observational studies: cohort,
caseecontrol and cross-sectional studies. Authors use diverse ter-
minology to describe these study designs. For instance, ‘follow-up
study’ and ‘longitudinal study’ are used as synonyms for ‘cohort
study’, and ‘prevalence study’ as synonymous with ‘cross-sectional
study’. We chose the present terminology because it is in common
use. Unfortunately, terminology is often used incorrectly [7] or
imprecisely [8]. In Box 1 we describe the hallmarks of the three
study designs.
1.2. The scope of observational research
Observational studies serve a wide range of purposes: from
reporting a ﬁrst hint of a potential cause of a disease, to verifying
themagnitude of previously reported associations. Ideas for studies
may arise from clinical observations or from biologic insight. Ideas
may also arise from informal looks at data that lead to further ex-
plorations. Like a clinician who has seen thousands of patients, and
notes one that strikes her attention, the researcher may note
something special in the data. Adjusting for multiple looks at the
data may not be possible or desirable [9], but further studies to
conﬁrm or refute initial observations are often needed [10]. Existing
data may be used to examine new ideas about potential causal
factors, and may be sufﬁcient for rejection or conﬁrmation. In other
instances, studies follow that are speciﬁcally designed to overcome
potential problems with previous reports. The latter studies will
gather new data and will be planned for that purpose, in contrast to
analyses of existing data. This leads to diverse viewpoints, e.g., on
the merits of looking at subgroups or the importance of a pre-
determined sample size. STROBE tries to accommodate these
diverse uses of observational research - from discovery to refuta-
tion or conﬁrmation. Where necessary we will indicate in what
circumstances speciﬁc recommendations apply.
1.3. How to use this paper
This paper is linked to the shorter STROBE paper that introduced
the items of the checklist in several journals [6], and forms an in-
tegral part of the STROBE Statement. Our intention is to explain
how to report research well, not how research should be done. We
offer a detailed explanation for each checklist item. Each explana-
tion is preceded by an example of what we consider transparent
reporting. This does not mean that the study from which the
example was taken was uniformly well reported or well done; nor
does it mean that its ﬁndings were reliable, in the sense that they
were later conﬁrmed by others: it only means that this particular
item was well reported in that study. In addition to explanations
and examples we included Boxes 1e8 with supplementary infor-
mation. These are intended for readers who want to refresh their
Box 1.
Main study designs covered by STROBE
Cohort, caseecontrol, and cross-sectional designs represent different approaches of investigating the occurrence of health-
related events in a given population and time period. These studies may address many types of health-related events,
including disease or disease remission, disability or complications, death or survival, and the occurrence of risk factors.
In cohort studies, the investigators follow people overtime. They obtain information about people and their exposures at baseline,
let time pass, and then assess the occurrence of outcomes. Investigators commonly make contrasts between individuals who are
exposed and not exposed or among groups of individuals with different categories of exposure. Investigators may assess several
different outcomes, and examine exposure and outcome variables at multiple points during follow-up. Closed cohorts (for
example birth cohorts) enrol a defined number of participants at study onset and follow them from that time forward, often at set
intervals up to a fixed end date. In open cohorts the study population is dynamic: people enter and leave the population at different
points in time (for example inhabitants of a town). Open cohorts change due to deaths, births, andmigration, but the composition
of the population with regard to variables such as age and gender may remain approximately constant, especially over a short
period of time. In a closed cohort cumulative incidences (risks) and incidence rates can be estimated; when exposed and unex-
posed groups are compared, this leads to risk ratio or rate ratio estimates. Open cohorts estimate incidence rates and rate ratios.
In caseecontrol studies, investigators compare exposures between people with a particular disease outcome (cases) and people
without that outcome (controls). Investigators aim to collect cases and controls that are representative of an underlying cohort or a
cross-section of a population. That population can be defined geographically, but also more loosely as the catchment area of
health care facilities. The case samplemay be 100% or a large fraction of available cases, while the control sample usually is only a
small fraction of the people who do not have the pertinent outcome. Controls represent the cohort or population of people from
which the cases arose. Investigators calculate the ratio of the odds of exposures to putative causes of the disease among cases and
controls (see Box 7). Depending on the sampling strategy for cases and controls and the nature of the population studied, the odds
ratio obtained in a caseecontrol study is interpreted as the risk ratio, rate ratio or (prevalence) odds ratio [16,17]. The majority of
published caseecontrol studies sample open cohorts and so allow direct estimations of rate ratios.
In cross-sectional studies, investigators assess all individuals in a sample at the same point in time, often to examine the
prevalence of exposures, risk factors or disease. Some cross-sectional studies are analytical and aim to quantify potential
causal associations between exposures and disease. Such studies may be analysed like a cohort study by comparing disease
prevalence between exposure groups. They may also be analysed like a caseecontrol study by comparing the odds of exposure
between groups with and without disease. A difficulty that can occur in any design but is particularly clear in cross-sectional
studies is to establish that an exposure preceded the disease, although the time order of exposure and outcome may some-
times be clear. In a study in which the exposure variable is congenital or genetic, for example, we can be confident that the
exposure preceded the disease, even if we are measuring both at the same time.
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memories about some theoretical points, or be quickly informed
about technical background details. A full understanding of these
points may require studying the textbooks or methodological pa-
pers that are cited.
STROBE recommendations do not speciﬁcally address topics
such as genetic linkage studies, infectious disease modelling or case
reports and case series [11,12]. As many of the key elements in
STROBE apply to these designs, authors who report such studies
may nevertheless ﬁnd our recommendations useful. For authors of
observational studies that speciﬁcally address diagnostic tests,
tumour markers and genetic associations, STARD [13], REMARK
[14], and STREGA [15] recommendationsmay be particularly useful.
1.4. The items in the STROBE checklist
We now discuss and explain the 22 items in the STROBE
checklist (Table 1), and give published examples for each item.
Some examples have been edited by removing citations or spelling
out abbreviations. Eighteen items apply to all three study designs
whereas four are design-speciﬁc. Starred items (for example item
8*) indicate that the information should be given separately for
cases and controls in caseecontrol studies, or exposed and unex-
posed groups in cohort and cross-sectional studies. We advise au-
thors to address all items somewhere in their paper, but we do not
prescribe a precise location or order. For instance, we discuss the
reporting of results under a number of separate items, while
recognizing that authors might address several items within a
single section of text or in a table.
2. The items
2.1. Title and Abstract
1(a). Indicate the study's design with a commonly used term in
the title or the abstract.
Example
“Leukaemia incidence among workers in the shoe and boot
manufacturing industry: a caseecontrol study” [18].
Explanation
Readers should be able to easily identify the design that was
used from the title or abstract. An explicit, commonly used term for
the study design also helps ensure correct indexing of articles in
electronic databases [19,20].
1(b). Provide in the abstract an informative and balanced sum-
mary of what was done and what was found.
Example
“Background: The expected survival of HIV-infected patients is
of major public health interest.
Box 2.
Matching in caseecontrol studies
In any caseecontrol study, sensible choices need to be made on whether to use matching of controls to cases, and if so, what
variables to match on, the precise method of matching to use, and the appropriate method of statistical analysis. Not to match at
all may mean that the distribution of some key potential confounders (e.g., age, sex) is radically different between cases and
controls. Although this could be adjusted for in the analysis there could be a major loss in statistical efficiency.
The use of matching in caseecontrol studies and its interpretation are fraught with difficulties, especially if matching is attempted
on several risk factors, some of whichmay be linked to the exposure of prime interest [50,51]. For example, in a caseecontrol study
of myocardial infarction and oral contraceptives nested in a large pharmacoepidemiologic database, with information about
thousands of women who are available as potential controls, investigators may be tempted to choose matched controls who had
similar levels of risk factors to each case of myocardial infarction. One objective is to adjust for factors that might influence the
prescription of oral contraceptives and thus to control for confounding by indication. However, the result will be a control group
that is no longer representative of the oral contraceptive use in the source population: controls will be older than the source
population because patients withmyocardial infarction tend to be older. This has several implications. A crude analysis of the data
will produce odds ratios that are usually biased towards unity if the matching factor is associated with the exposure. The solution
is to perform a matched or stratified analysis (see item 12d). In addition, because the matched control group ceases to be
representative for the population at large, the exposure distribution among the controls can no longer be used to estimate the
population attributable fraction (see Box 7) [52]. Also, the effect of thematching factor can no longer be studied, and the search for
well-matched controls can be cumbersome e making a design with a non-matched control group preferable because the non-
matched controls will be easier to obtain and the control group can be larger. Overmatching is another problem, which may
reduce the efficiency of matched caseecontrol studies, and, in some situations, introduce bias. Information is lost and the power
of the study is reduced if the matching variable is closely associated with the exposure. Then many individuals in the same
matched sets will tend to have identical or similar levels of exposures and therefore not contribute relevant information. Matching
will introduce irremediable bias if the matching variable is not a confounder but in the causal pathway between exposure and
disease. For example, in vitro fertilization is associated with an increased risk of perinatal death, due to an increase in multiple
births and low birth weight infants [53]. Matching on plurality or birth weight will bias results towards the null, and this cannot be
remedied in the analysis.
Matching is intuitively appealing, but the complexities involved have led methodologists to advise against routine matching in
caseecontrol studies. They recommend instead a careful and judicious consideration of each potential matching factor, recog-
nizing that it could instead be measured and used as an adjustment variable without matching on it. In response, there has been a
reduction in the number of matching factors employed, an increasing use of frequency matching, which avoids some of the
problems discussed above, andmore caseecontrol studies with nomatching at all [54]. Matching remainsmost desirable, or even
necessary, when the distributions of the confounder (e.g., age) might differ radically between the unmatched comparison groups
[48,49].
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Objective: To estimate survival time and age-speciﬁc mortality
rates of an HIV-infected population compared with that of the
general population.
Design: Population-based cohort study.
Setting: All HIV-infected persons receiving care in Denmark
from 1995 to 2005.
Patients: Each member of the nationwide Danish HIV Cohort
Study was matched with as many as 99 persons from the general
population according to sex, date of birth, and municipality of
residence.
Measurements: The authors computed KaplaneMeier life
tables with age as the time scale to estimate survival from age
25 years. Patients with HIV infection and corresponding per-
sons from the general population were observed from the date
of the patient's HIV diagnosis until death, emigration, or 1 May
2005.
Results: 3990 HIV-infected patients and 379,872 persons from
the general population were included in the study, yielding
22,744 (median, 5.8 years/person) and 2,689,287 (median, 8.4
years/person) person-years of observation. Three percent of
participants were lost to follow-up. From age 25 years, the me-
dian survival was 19.9 years (95% CI, 18.5 to 21.3) among patients
with HIV infection and 51.1 years (CI, 50.9 to 51.5) among the
general population. For HIV-infected patients, survival increased
to 32.5 years (CI, 29.4 to 34.7) during the 2000 to 2005 period. In
the subgroup that excluded persons with known hepatitis C co-
infection (16%), median survival was 38.9 years (CI, 35.4 to 40.1)
during this same period. The relative mortality rates for patients
with HIV infection compared with those for the general popu-
lation decreased with increasing age, whereas the excess mor-
tality rate increased with increasing age.
Limitations: The observed mortality rates are assumed to apply
beyond the current maximum observation time of 10 years.
Conclusions: The estimated median survival is more than 35
years for a young person diagnosed with HIV infection in the late
highly active antiretroviral therapy era. However, an ongoing effort
is still needed to further reduce mortality rates for these persons
compared with the general population” [21].
Explanation
The abstract provides key information that enables readers to
understand a study and decide whether to read the article.
Typical components include a statement of the research ques-
tion, a short description of methods and results, and a conclusion
[22]. Abstracts should summarize key details of studies and
should only present information that is provided in the article.
We advise presenting key results in a numerical form that in-
cludes numbers of participants, estimates of associations and
appropriate measures of variability and uncertainty (e.g., odds
ratios with conﬁdence intervals). We regard it insufﬁcient to
state only that an exposure is or is not signiﬁcantly associated
with an outcome.
A series of headings pertaining to the background, design,
conduct, and analysis of a study may help readers acquire the
essential information rapidly [23]. Many journals require such
structured abstracts, which tend to be of higher quality and more
readily informative than unstructured summaries [24,25].
Box 3.
Bias
Bias is a systematic deviation of a study's result from a true value. Typically, it is introduced during the design or implementation
of a study and cannot be remedied later. Bias and confounding are not synonymous. Bias arises from flawed information or
subject selection so that a wrong association is found. Confounding produces relations that are factually right, but that cannot be
interpreted causally because some underlying, unaccounted for factor is associated with both exposure and outcome (see Box 5).
Also, bias needs to be distinguished from random error, a deviation from a true value caused by statistical fluctuations (in either
direction) in the measured data. Many possible sources of bias have been described and a variety of terms are used [68,69]. We
find two simple categories helpful: information bias and selection bias.
Information bias occurs when systematic differences in the completeness or the accuracy of data lead to differential misclassi-
fication of individuals regarding exposures or outcomes. For instance, if diabetic women receive more regular and thorough eye
examinations, the ascertainment of glaucoma will be more complete than in women without diabetes (see item 9) [65]. Patients
receiving a drug that causes non-specific stomach discomfort may undergo gastroscopy more often and have more ulcers
detected than patients not receiving the drug e even if the drug does not cause more ulcers. This type of information bias is also
called ‘detection bias’ or ‘medical surveillance bias’. One way to assess its influence is to measure the intensity of medical sur-
veillance in the different study groups, and to adjust for it in statistical analyses. In caseecontrol studies information bias occurs if
cases recall past exposures more or less accurately than controls without that disease, or if they are more or less willing to report
them (also called ‘recall bias’). ‘Interviewer bias’ can occur if interviewers are aware of the study hypothesis and subconsciously or
consciously gather data selectively [70]. Some form of blinding of study participants and researchers is therefore often valuable.
Selection bias may be introduced in caseecontrol studies if the probability of including cases or controls is associated with
exposure. For instance, a doctor recruiting participants for a study on deep-vein thrombosis might diagnose this disease in a
womanwho has leg complaints and takes oral contraceptives. But shemight not diagnose deep-vein thrombosis in a womanwith
similar complaints who is not taking suchmedication. Such bias may be countered by using cases and controls that were referred
in the same way to the diagnostic service [71]. Similarly, the use of disease registers may introduce selection bias: if a possible
relationship between an exposure and a disease is known, casesmay bemore likely to be submitted to a register if they have been
exposed to the suspected causative agent [72]. ‘Response bias’ is another type of selection bias that occurs if differences in
characteristics between those who respond and those who decline participation in a study affect estimates of prevalence, inci-
dence and, in some circumstances, associations. In general, selection bias affects the internal validity of a study. This is different
from problems that may arise with the selection of participants for a study in general, which affects the external rather than the
internal validity of a study (also see item 21).
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2.2. Introduction
The Introduction section should describe why the study was
done and what questions and hypotheses it addresses. It should
allow others to understand the study's context and judge its po-
tential contribution to current knowledge.
2. Background/rationale: Explain the scientiﬁc background and
rationale for the investigation being reported.
Example
“Concerns about the rising prevalence of obesity in children and
adolescents have focused on the well documented associations
between childhood obesity and increased cardiovascular risk and
mortality in adulthood. Childhood obesity has considerable social
and psychological consequences within childhood and adoles-
cence, yet little is known about social, socioeconomic, and psy-
chological consequences in adult life. A recent systematic review
found no longitudinal studies on the outcomes of childhood obesity
other than physical health outcomes and only two longitudinal
studies of the socioeconomic effects of obesity in adolescence.
Gortmaker et al. found that US women who had been obese in late
adolescence in 1981 were less likely to be married and had lower
Box 4.
Grouping
There are several reasons why continuous data may be
grouped [86]. When collecting data it may be better to use
an ordinal variable than to seek an artificially precise
continuous measure for an exposure based on recall over
several years. Categories may also be helpful for presen-
tation, for example to present all variables in a similar style,
or to show a doseeresponse relationship.
Grouping may also be done to simplify the analysis, for
example to avoid an assumption of linearity. However,
grouping loses information and may reduce statistical po-
wer [87] especially when dichotomization is used [82,85,88].
If a continuous confounder is grouped, residual confound-
ingmay occur, whereby some of the variable's confounding
effect remains unadjusted for (see Box 5) [62,89]. Increasing
the number of categories can diminish power loss and re-
sidual confounding, and is especially appropriate in large
studies. Small studies may use few groups because of
limited numbers.
Investigators may choose cut-points for groupings based
on commonly used values that are relevant for diagnosis or
prognosis, for practicality, or on statistical grounds. They
may choose equal numbers of individuals in each group
using quantiles [90]. On the other hand, one may gain more
insight into the association with the outcome by choosing
more extreme outer groups and having the middle group(s)
larger than the outer groups [91]. In caseecontrol studies,
deriving a distribution from the control group is preferred
since it is intended to reflect the source population. Readers
should be informed if cut-points are selected post hoc from
several alternatives. In particular, if the cut-points were
chosen to minimise a P value the true strength of an asso-
ciation will be exaggerated [81].
When analysing grouped variables, it is important to
recognise their underlying continuous nature. For instance,
a possible trend in risk across ordered groups can be
investigated. A common approach is to model the rank of
the groups as a continuous variable. Such linearity across
group scores will approximate an actual linear relation if
groups are equally spaced (e.g., 10 year age groups) but not
otherwise. Il'yasova et al. [92] recommend publication of
both the categorical and the continuous estimates of effect,
with their standard errors, in order to facilitate meta-
analysis, as well as providing intrinsically valuable infor-
mation on doseeresponse. One analysis may inform the
other and neither is assumption-free. Authors often ignore
the ordering and consider the estimates (and P values)
separately for each category compared to the reference
category. This may be useful for description, but may fail to
detect a real trend in risk across groups. If a trend is
observed, a confidence interval for a slope might indicate
the strength of the observation.
Box 5.
Confounding
Confounding literally means confusion of effects. A study
might seem to show either an association or no association
between an exposure and the risk of a disease. In reality, the
seeming association or lack of association is due to another
factor that determines the occurrence of the disease but that
is also associated with the exposure. The other factor is
called the confounding factor or confounder. Confounding
thus gives a wrong assessment of the potential ‘causal’
association of an exposure. For example, if women who
approach middle age and develop elevated blood pressure
are less often prescribed oral contraceptives, a simple
comparison of the frequency of cardiovascular disease be-
tween those who use contraceptives and those who do not,
might give the wrong impression that contraceptives pro-
tect against heart disease.
Investigators should think beforehand about potential
confounding factors. This will inform the study design and
allow proper data collection by identifying the confounders
for which detailed information should be sought. Restric-
tion or matching may be used. In the example above, the
study might be restricted to women who do not have the
confounder, elevated blood pressure. Matching on blood
pressure might also be possible, though not necessarily
desirable (see Box 2). In the analysis phase, investigators
may use stratification or multivariable analysis to reduce
the effect of confounders. Stratification consists of dividing
the data in strata for the confounder (e.g., strata of blood
pressure), assessing estimates of association within each
stratum, and calculating the combined estimate of associ-
ation as a weighted average over all strata. Multivariable
analysis achieves the same result but permits one to take
more variables into account simultaneously. It is more
flexible but may involve additional assumptions about the
mathematical form of the relationship between exposure
and disease.
Taking confounders into account is crucial in observational
studies, but readers should not assume that analyses
adjusted for confounders establish the ‘causal part’ of an
association. Results may still be distorted by residual con-
founding (the confounding that remains after unsuccessful
attempts to control for it [102]), random sampling error,
selection bias and information bias (see Box 3).
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incomes seven years later than women who had not been over-
weight, while menwho had been overweight were less likely to be
married. Sargent et al. found that UKwomen, but notmen, who had
been obese at 16 years in 1974 earned 7.4% less than their non-
obese peers at age 23. (…) We used longitudinal data from the
1970 British birth cohort to examine the adult socioeconomic,
educational, social, and psychological outcomes of childhood
obesity” [26].
Explanation
The scientiﬁc background of the study provides important
context for readers. It sets the stage for the study and describes its
focus. It gives an overview of what is known on a topic and what
gaps in current knowledge are addressed by the study. Background
material should note recent pertinent studies and any systematic
reviews of pertinent studies.
3. Objectives: State speciﬁc objectives, including any pre-spec-
iﬁed hypotheses.
Example
“Our primary objectives were to 1) determine the prevalence of
domestic violence among female patients presenting to four
community-based, primary care, adult medicine practices that
serve patients of diverse socio background and 2) identify de-
mographic and clinical differences between currently abused pa-
tients and patients not currently being abused ” [27].
Explanation
Objectives are the detailed aims of the study. Well crafted ob-
jectives specify populations, exposures and outcomes, and pa-
rameters that will be estimated. They may be formulated as speciﬁc
hypotheses or as questions that the study was designed to address.
In some situations objectives may be less speciﬁc, for example, in
early discovery phases. Regardless, the report should clearly reﬂect
the investigators' intentions. For example, if important subgroups
or additional analyses were not the original aim of the study but
arose during data analysis, they should be described accordingly
(see also items 4, 17 and 20).
2.3. Methods
The Methods section should describe what was planned and
what was done in sufﬁcient detail to allow others to understand the
essential aspects of the study, to judge whether the methods were
adequate to provide reliable and valid answers, and to assess
whether any deviations from the original plan were reasonable.
4. Study design: Present key elements of study design early in
the paper.
Example
“We used a case-crossover design, a variation of a caseecontrol
design that is appropriate when a brief exposure (driver's phone
use) causes a transient rise in the risk of a rare outcome (a crash).
We compared a driver's use of a mobile phone at the estimated
time of a crash with the same driver's use during another suitable
time period. Because drivers are their own controls, the design
controls for characteristics of the driver that may affect the risk of a
crash but do not change over a short period of time. As it is
important that risks during control periods and crash trips are
similar, we compared phone activity during the hazard interval
(time immediately before the crash) with phone activity during
control intervals (equivalent times during which participants were
driving but did not crash) in the previous week” [28].
Explanation
We advise presenting key elements of study design early in the
methods section (or at the end of the introduction) so that readers
can understand the basics of the study. For example, authors should
indicate that the study was a cohort study, which followed people
over a particular time period, and describe the group of persons
that comprised the cohort and their exposure status. Similarly, if
the investigation used a caseecontrol design, the cases and controls
and their source population should be described. If the study was a
cross-sectional survey, the population and the point in time at
which the cross-section was taken should be mentioned. When a
study is a variant of the three main study types, there is an
Box 6.
Missing data: problems and possible solutions
A common approach to dealing with missing data is to
restrict analyses to individuals with complete data on all
variables required for a particular analysis. Although such
‘complete-case’ analyses are unbiased in many circum-
stances, they can be biased and are always inefficient [108].
Bias arises if individuals with missing data are not typical of
the whole sample. Inefficiency arises because of the
reduced sample size for analysis.
Using the last observation carried forward for repeated
measures can distort trends over time if persons who
experience a foreshadowing of the outcome selectively
drop out [109]. Inserting a missing category indicator for a
confounder may increase residual confounding [107].
Imputation, in which each missing value is replaced with an
assumed or estimated value, may lead to attenuation or
exaggeration of the association of interest, and without the
use of sophisticated methods described below may pro-
duce standard errors that are too small.
Rubin developed a typology of missing data problems,
based on a model for the probability of an observation be-
ing missing [108,110]. Data are described as missing
completely at random (MCAR) if the probability that a
particular observation is missing does not depend on the
value of any observable variable(s). Data are missing at
random (MAR) if, given the observed data, the probability
that observations are missing is independent of the actual
values of the missing data. For example, suppose younger
children are more prone to missing spirometry measure-
ments, but that the probability of missing is unrelated to the
true unobserved lung function, after accounting for age.
Then the missing lung function measurement would be
MAR in models including age. Data are missing not at
random (MNAR) if the probability of missing still depends
on the missing value even after taking the available data
into account. When data are MNAR valid inferences require
explicit assumptions about the mechanisms that led to
missing data.
Methods to deal with datamissing at random (MAR) fall into
three broad classes [108,111]: likelihood-based approaches
[112], weighted estimation [113] and multiple imputation
[111,114]. Of these three approaches, multiple imputation is
the most commonly used and flexible, particularly when
multiple variables have missing values [115]. Results using
any of these approaches should be compared with those
from complete case analyses, and important differences
discussed. The plausibility of assumptions made in missing
data analyses is generally unverifiable. In particular it is
impossible to prove that data are MAR, rather than MNAR.
Such analyses are therefore best viewed in the spirit of
sensitivity analysis (see items 12e and 17).
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additional need for clarity. For instance, for a case-crossover study,
one of the variants of the caseecontrol design, a succinct descrip-
tion of the principles was given in the example above [28].
We recommend that authors refrain from simply calling a study
‘prospective’ or ‘retrospective’ because these terms are ill deﬁned
[29]. One usage sees cohort and prospective as synonymous and
reserves the word retrospective for caseecontrol studies [30]. A
second usage distinguishes prospective and retrospective cohort
studies according to the timing of data collection relative to when
the idea for the study was developed [31]. A third usage distin-
guishes prospective and retrospective caseecontrol studies
depending on whether the data about the exposure of interest
existed when cases were selected [32]. Some advise against using
these terms [33], or adopting the alternatives ‘concurrent’ and
‘historical’ for describing cohort studies [34]. In STROBE, we do not
use the words prospective and retrospective, nor alternatives such
as concurrent and historical. We recommend that, whenever au-
thors use these words, they deﬁne what they mean. Most impor-
tantly, we recommend that authors describe exactly how andwhen
data collection took place.
The ﬁrst part of the methods section might also be the place to
mention whether the report is one of several from a study. If a new
report is in line with the original aims of the study, this is usually
indicated by referring to an earlier publication and by brieﬂy
restating the salient features of the study. However, the aims of a
study may also evolve over time.
Researchers often use data for purposes for which theywere not
originally intended, including, for example, ofﬁcial vital statistics
that were collected primarily for administrative purposes, items in
questionnaires that originally were only included for completeness,
or blood samples that were collected for another purpose. For
example, the Physicians' Health Study, a randomized controlled
trial of aspirin and carotene, was later used to demonstrate that a
point mutation in the factor V gene was associated with an
increased risk of venous thrombosis, but not of myocardial infarc-
tion or stroke [35]. The secondary use of existing data is a creative
part of observational research and does not necessarily make re-
sults less credible or less important. However, brieﬂy restating the
original aims might help readers understand the context of the
research and possible limitations in the data.
5. Setting: Describe the setting, locations, and relevant dates,
including periods of recruitment, exposure, follow-up, and data
collection.
Example
“The Pasitos Cohort Study recruited pregnant women from
Women, Infant and Child clinics in Socorro and San Elizario, El Paso
County, Texas and maternal-child clinics of the Mexican Social Se-
curity Institute in Ciudad Juarez, Mexico from April 1998 to October
2000. At baseline, prior to the birth of the enrolled cohort children,
staff interviewed mothers regarding the household environment.
In this ongoing cohort study, we target follow-up exams at 6-
month intervals beginning at age 6 months” [36].
Explanation
Readers need information on setting and locations to assess the
context and generalisability of a study's results. Exposures such as
environmental factors and therapies can change over time. Also,
Box 7.
Measures of association, effect and impact
Observational studies may be solely done to describe the magnitude and distribution of a health problem in the population. They
may examine the number of people who have a disease at a particular time (prevalence), or that develop a disease over a defined
period (incidence). The incidence may be expressed as the proportion of people developing the disease (cumulative incidence) or
as a rate per person-time of follow-up (incidence rate). Specific terms are used to describe different incidences; amongst others,
mortality rate, birth rate, attack rate, or case fatality rate. Similarly, terms like point prevalence and period, annual or lifetime
prevalence are used to describe different types of prevalence [30].
Other observational studies address causeeeffect relationships. Their focus is the comparison of the risk, rate or prevalence of the
event of interest between those exposed and those not exposed to the risk factor under investigation. These studies often estimate
a ‘relative risk’, which may stand for risk ratios (ratios of cumulative incidences) as well as rate ratios (ratios of incidence rates). In
caseecontrol studies only a fraction of the source population (the controls) are included. Results are expressed as the ratio of the
odds of exposure among cases and controls. This odds ratio provides an estimate of the risk or rate ratio depending on the
sampling of cases and controls (see also Box 1) [175,176]. The prevalence ratio or prevalence odds ratio from cross-sectional
studies may be useful in some situations [177].
Expressing results both in relative and absolute terms may often be helpful. For example, in a study of male British doctors the
incidence rate of death from lung cancer over 50 years of follow-up was 249 per 100,000 per year among smokers, compared to 17
per 100,000 per year among non-smokers: a rate ratio of 14.6 (249/17) [178]. For coronary heart disease (CHD), the corresponding
rates were 1001 and 619 per 100,000 per year, for a rate ratio of 1.61 (1001/619). The effect of smoking on death appears much
stronger for lung cancer than for CHD. The picture changes when we consider the absolute effects of smoking. The difference in
incidence rates was 232 per 100,000 per year (249e17) for lung cancer and 382 for CHD (1001e619). Therefore, among doctors who
smoked, smoking was more likely to cause death from CHD than from lung cancer.
How much of the disease burden in a population could be prevented by eliminating an exposure? Global estimates have been
published for smoking: according to one study 91% of all lung cancers, 40% of CHD and 33% of all deaths amongmen in 2000were
attributed to smoking [179]. The population attributable fraction is generally defined as the proportion of cases caused by a
particular exposure, but several concepts (and no unified terminology) exist, and incorrect approaches to adjust for other factors
are sometimes used [172,180]. What are the implications for reporting? The relative measures emphasise the strength of an
association, and are most useful in etiologic research. If a causal relationship with an exposure is documented and associations
are interpreted as effects, estimates of relative risk may be translated into suitable measures of absolute risk in order to gauge the
possible impact of public health policies (see item 16c) [181]. However, authors should be aware of the strong assumptions made
in this context [171]. Care is needed in deciding which concept and method is appropriate for a particular situation.
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study methods may evolve over time. Knowing when a study took
place and over what period participants were recruited and fol-
lowed-up places the study in historical context and is important for
the interpretation of results.
Information about setting includes recruitment sites or sources
(e.g., electoral roll, outpatient clinic, cancer registry, or tertiary care
centre). Information about locationmay refer to the countries, towns,
hospitals or practices where the investigation took place. We advise
stating dates rather than only describing the length of time periods.
Theremay be different sets of dates for exposure, disease occurrence,
recruitment, beginning and end of follow-up, and data collection. Of
note, nearly80%of132reports inoncology journals thatusedsurvival
analysis included the startingandendingdates foraccrualofpatients,
but only 24% also reported the date onwhich follow-up ended [37].
6. Participants:
6(a). Cohort study: Give the eligibility criteria, and the sources
and methods of selection of participants. Describe methods of
follow-up.
Example
“Participants in the IowaWomen's Health Study were a random
sample of all women ages 55 to 69 years derived from the state of
Iowa automobile driver's license list in 1985, which represented
approximately 94% of Iowawomen in that age group. (…) Follow-up
questionnaires were mailed in October 1987 and August 1989 to
assess vital status and address changes. (…) Incident cancers, except
for non-melanoma skin cancers, were ascertained by the State
Health Registry of Iowa (…). The IowaWomen's Health Study cohort
was matched to the registry with combinations of ﬁrst, last, and
maidennames, zip code, birthdate, and social security number” [38].
6(a). Caseecontrol study: give the eligibility criteria, and the
sources and methods of case ascertainment and control selection.
Give the rationale for the choice of cases and controls.
Example
“Cutaneous melanoma cases diagnosed in 1999 and 2000 were
ascertained through the Iowa Cancer Registry (…). Controls, also
identiﬁed through the Iowa Cancer Registry, were colorectal cancer
patients diagnosed during the same time. Colorectal cancer con-
trols were selected because they are common and have a relatively
long survival, and because arsenic exposure has not been conclu-
sively linked to the incidence of colorectal cancer” [39].
6(a). Cross-sectional study: give the eligibility criteria, and the
sources and methods of selection of participants.
Example
“We retrospectively identiﬁed patients with a principal diag-
nosis of myocardial infarction (code 410) according to the Inter-
national Classiﬁcation of Diseases, 9th Revision, Clinical
Modiﬁcation, from codes designating discharge diagnoses,
excluding the codes with a ﬁfth digit of 2, which designates a
subsequent episode of care (…) A random sample of the entire
Medicare cohort with myocardial infarction from February 1994 to
July 1995 was selected (…) To be eligible, patients had to present to
the hospital after at least 30 minutes but less than 12 hours of chest
pain and had to have ST-segment elevation of at least 1 mm on two
contiguous leads on the initial electrocardiogram” [40].
Explanation
Detailed descriptions of the study participants help readers
understand the applicability of the results. Investigators usually
restrict a study population by deﬁning clinical, demographic and
other characteristics of eligible participants. Typical eligibility
criteria relate to age, gender, diagnosis and comorbid conditions.
Despite their importance, eligibility criteria often are not reported
adequately. In a survey of observational stroke research, 17 of 49
reports (35%) did not specify eligibility criteria [5].
Eligibility criteria may be presented as inclusion and exclusion
criteria, although this distinction is not always necessary or useful.
Regardless, we advise authors to report all eligibility criteria and
also to describe the group from which the study population was
selected (e.g., the general population of a region or country), and
Box 8.
Interaction (effect modification): the analysis of joint effects
Interaction exists when the association of an exposure with
the risk of disease differs in the presence of another expo-
sure. One problem in evaluating and reporting interactions
is that the effect of an exposure can be measured in two
ways: as a relative risk (or rate ratio) or as a risk difference
(or rate difference). The use of the relative risk leads to a
multiplicative model, while the use of the risk difference
corresponds to an additive model [187,188]. A distinction is
sometimesmade between ‘statistical interaction’which can
be a departure from either a multiplicative or additive
model, and ‘biologic interaction’ which is measured by
departure from an additive model [189]. However, neither
additive nor multiplicative models point to a particular
biologic mechanism.
Regardless of the model choice, the main objective is to
understand how the joint effect of two exposures differs
from their separate effects (in the absence of the other
exposure). The Human Genomic Epidemiology Network
(HuGENet) proposed a lay-out for transparent presentation
of separate and joint effects that permits evaluation of
different types of interaction [183]. Data from the study on
oral contraceptives and factor V Leidenmutation [182] were
used to explain the proposal, and this example is also used
in item 17. Oral contraceptives and factor V Leidenmutation
each increase the risk of venous thrombosis; their separate
and joint effects can be calculated from the 2 by 4 table (see
example 1 for item 17) where the odds ratio of 1 denotes the
baseline of women without Factor V Leiden who do not use
oral contraceptives.
A difficulty is that some study designs, such as caseecontrol
studies, and several statistical models, such as logistic or
Cox regressionmodels, estimate relative risks (or rate ratios)
and intrinsically lead to multiplicative modelling. In these
instances, relative riskscanbe translated toanadditivescale.
In example 1 of item 17, the separate odds ratios are 3.7 and
6.9; the joint odds ratio is 34.7.When thesedata are analysed
under a multiplicative model, a joint odds ratio of 25.7 is
expected (3.7  6.9). The observed joint effect of 34.7 is 1.4
times greater than expected on a multiplicative scale (34.7/
25.7). This quantity (1.4) is theodds ratio of themultiplicative
interaction. It would be equal to the antilog of the estimated
interaction coefficient from a logistic regression model.
Underanadditivemodel the jointodds ratio is expected tobe
9.6 (3.7 þ 6.9e1). The observed joint effect departs strongly
from additivity: the difference is 25.1 (34.7e9.6). When odds
ratios are interpreted as relative risks (or rate ratios), the
latter quantity (25.1) is the Relative Excess Risk from Inter-
action (RERI) [190]. This can be understood more easily
when imagining that the reference value (equivalent to
OR ¼ 1) represents a baseline incidence of venous throm-
bosis of, say, 1/10,000women-years,which then increases in
the presence of separate and joint exposures.
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the method of recruitment (e.g., referral or self-selection through
advertisements).
Knowing details about follow-up procedures, including whether
procedures minimized non-response and loss to follow-up and
whether the procedures were similar for all participants, informs
judgments about the validity of results. For example, in a study that
used IgM antibodies to detect acute infections, readers needed to
knowthe intervalbetweenbloodtests for IgMantibodies so that they
could judgewhether some infections likelyweremissed because the
interval between blood tests was too long [41]. In other studies
where follow-up procedures differed between exposed and unex-
posed groups, readers might recognize substantial bias due to un-
equal ascertainment of events or differences in non-response or loss
to follow-up [42]. Accordingly, we advise that researchers describe
the methods used for following participants and whether those
methods were the same for all participants, and that they describe
the completeness of ascertainment of variables (see also item 14).
In caseecontrol studies, the choice of cases and controls is crucial
to interpreting the results, and the method of their selection has
major implications for study validity. In general, controls should
reﬂect the population fromwhich the cases arose. Various methods
are used to sample controls, all with advantages and disadvantages:
for cases that arise from a general population, population roster
sampling, random-digit dialling, neighbourhood or friend controls
are used. Neighbourhood or friend controls may present intrinsic
matching on exposure [17]. Controls with other diseases may have
advantages over population-based controls, in particular for
hospital-based cases, because they better reﬂect the catchment
population of a hospital, have greater comparability of recall and
ease of recruitment. However, they can present problems if the
exposure of interest affects the risk of developing or being hospi-
talized for the control condition(s) [43,44]. To remedy this problem
often a mixture of the best defensible control diseases is used [45].
6(b). Cohort study: For matched studies, give matching criteria
and number of exposed and unexposed.
Example
“For each patient who initially received a statin, we used
propensity-based matching to identify one control who did not
receive a statin according to the following protocol. First, propensity
scores were calculated for each patient in the entire cohort on the
basis of an extensive list of factors potentially related to the use of
statins or the risk of sepsis. Second, each statin userwasmatched to a
smaller pool of non-statin-users by sex, age (plus or minus 1 year),
and index date (plus or minus 3 months). Third, we selected the
controlwith theclosestpropensity score (within0.2SD) toeachstatin
user in a 1:1 fashion and discarded the remaining controls.” [46].
6(b). Caseecontrol study: For matched studies, give matching
criteria and the number of controls per case.
Example
“We aimed to select ﬁve controls for every case from among in-
dividuals in the study populationwho had no diagnosis of autism or
other pervasive developmental disorders (PDD) recorded in their
general practice record and who were alive and registered with a
participating practice on the date of the PDD diagnosis in the case.
Controls were individually matched to cases by year of birth (up to 1
yearolderoryounger), sex, andgeneralpractice. Foreachof300cases,
ﬁve controls couldbe identiﬁedwhomet all thematching criteria. For
the remaining 994, one or more controls was excluded…” [47].
Explanation
Matching is much more common in caseecontrol studies, but
occasionally, investigators use matching in cohort studies to make
groups comparable at the start of follow-up. Matching in cohort
studies makes groups directly comparable for potential con-
founders and presents fewer intricacies than with caseecontrol
studies. For example, it is not necessary to take the matching into
account for the estimation of the relative risk [48]. Because
matching in cohort studies may increase statistical precision in-
vestigators might allow for the matching in their analyses and thus
obtain narrower conﬁdence intervals.
In caseecontrol studies matching is done to increase a study's
efﬁciency by ensuring similarity in the distribution of variables
between cases and controls, in particular the distribution of po-
tential confounding variables [48,49]. Because matching can be
done in various ways, with one or more controls per case, the
rationale for the choice of matching variables and the details of the
method used should be described. Commonly used forms of
matching are frequency matching (also called groupmatching) and
individual matching. In frequency matching, investigators choose
controls so that the distribution of matching variables becomes
identical or similar to that of cases. Individual matching involves
matching one or several controls to each case. Although intuitively
appealing and sometimes useful, matching in caseecontrol studies
has a number of disadvantages, is not always appropriate, and
needs to be taken into account in the analysis (see Box 2).
Even apparently simple matching procedures may be poorly re-
ported. Forexample, authorsmaystate that controlswerematched to
cases ‘withinﬁveyears’, or using ‘ﬁveyearage bands’. Does thismean
that, if a casewas 54 years old, the respective control needed to be in
the ﬁve-year age band 50 to 54, or aged 49 to 59,which iswithin ﬁve
years of age 54? If a wide (e.g., 10-year) age band is chosen, there is a
danger of residual confounding by age (see also Box 4), for example
because controls may then be younger than cases on average.
7. Variables: Clearly deﬁne all outcomes, exposures, predictors,
potential confounders, and effect modiﬁers. Give diagnostic
criteria, if applicable.
Example
“Only major congenital malformations were included in the
analyses. Minor anomalies were excluded according to the exclu-
sion list of European Registration of Congenital Anomalies (EURO-
CAT). If a child had more than one major congenital malformation
of one organ system, those malformations were treated as one
outcome in the analyses by organ system (…). In the statistical
analyses, factors considered potential confounders were maternal
age at delivery and number of previous parities. Factors considered
potential effect modiﬁers were maternal age at reimbursement for
antiepileptic medication and maternal age at delivery” [55].
Explanation
Authors should deﬁne all variables considered for and included
in the analysis, including outcomes, exposures, predictors, potential
confounders and potential effect modiﬁers. Disease outcomes
require adequately detailed description of the diagnostic criteria.
This applies to criteria for cases in a caseecontrol study, disease
events during follow-up in a cohort study and prevalent disease in a
cross-sectional study. Clear deﬁnitions and steps taken to adhere to
them are particularly important for any disease condition of pri-
mary interest in the study.
For some studies, ‘determinant’ or ‘predictor’maybe appropriate
terms for exposure variables and outcomes may be called ‘end-
points’. Inmultivariablemodels, authors sometimes use ‘dependent
variable’ for an outcome and ‘independent variable’ or ‘explanatory
variable’ for exposure and confounding variables. The latter is not
precise as it does not distinguish exposures from confounders.
If many variables have been measured and included in explor-
atory analyses in an early discovery phase, consider providing a list
with details on each variable in an appendix, additional table or
separate publication. Of note, the International Journal of Epidemi-
ology recently launched a new section with ‘cohort proﬁles’, that
includes detailed information on what was measured at different
points in time in particular studies [56,57]. Finally, we advise that
authors declare all ‘candidate variables’ considered for statistical
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analysis, rather than selectively reporting only those included in
the ﬁnal models (see also item 16a) [58,59].
8. Data sources/measurement: For each variable of interest give
sources of data and details of methods of assessment (measure-
ment). Describe comparability of assessment methods if there is
more than one group.
Example 1
“Total caffeine intake was calculated primarily using US
Department of Agriculture food composition sources. In these cal-
culations, it was assumed that the content of caffeine was 137 mg
per cup of coffee, 47 mg per cup of tea, 46 mg per can or bottle of
cola beverage, and 7 mg per serving of chocolate candy. This
method of measuring (caffeine) intake was shown to be valid in
both the NHS I cohort and a similar cohort study of male health
professionals (…). Self-reported diagnosis of hypertension was
found to be reliable in the NHS I cohort” [60].
Example 2
“Samples pertaining to matched cases and controls were always
analysed together in the same batch and laboratory personnel were
unable to distinguish among cases and controls” [61].
Explanation
The way in which exposures, confounders and outcomes were
measured affects the reliability and validity of a study. Measure-
ment error and misclassiﬁcation of exposures or outcomes can
make it more difﬁcult to detect causeeeffect relationships, or may
produce spurious relationships. Error in measurement of potential
confounders can increase the risk of residual confounding [62,63].
It is helpful, therefore, if authors report the ﬁndings of any studies
of the validity or reliability of assessments or measurements,
including details of the reference standard that was used. Rather
than simply citing validation studies (as in the ﬁrst example), we
advise that authors give the estimated validity or reliability, which
can then be used for measurement error adjustment or sensitivity
analyses (see items 12e and 17).
In addition, it is important to know if groups being compared
differed with respect to the way in which the data were collected.
This may be important for laboratory examinations (as in the sec-
ond example) and other situations. For instance, if an interviewer
ﬁrst questions all the cases and then the controls, or vice versa, bias
is possible because of the learning curve; solutions such as ran-
domising the order of interviewing may avoid this problem. In-
formation bias may also arise if the compared groups are not given
the same diagnostic tests or if one group receives more tests of the
same kind than another (see also item 9).
9. Bias: describe any efforts to address potential sources of bias.
Example 1
“In most caseecontrol studies of suicide, the control group
comprises living individuals but we decided to have a control group
of people who had died of other causes (…). With a control group of
deceased individuals, the sources of information used to assess risk
factors are informants who have recently experienced the death of
a family member or close associate - and are therefore more
comparable to the sources of information in the suicide group than
if living controls were used” [64].
Example 2
“Detection bias could inﬂuence the association between Type 2
diabetes mellitus (T2DM) and primary open-angle glaucoma
(POAG) if women with T2DM were under closer ophthalmic sur-
veillance than women without this condition. We compared the
mean number of eye examinations reported by women with and
without diabetes. We also recalculated the relative risk for POAG
with additional control for covariates associated with more careful
ocular surveillance (a self-report of cataract, macular degeneration,
number of eye examinations, and number of physical examina-
tions)” [65].
Explanation
Biased studies produce results that differ systematically from the
truth (see also Box 3). It is important for a reader to know what
measures were taken during the conduct of a study to reduce the
potential of bias. Ideally, investigators carefully consider potential
sources of bias when they plan their study. At the stage of reporting,
we recommend that authors always assess the likelihood of relevant
biases. Speciﬁcally, the direction and magnitude of bias should be
discussed and, if possible, estimated. For instance, in caseecontrol
studies information bias can occur, but may be reduced by selecting
an appropriate control group, as in the ﬁrst example [64]. Differ-
ences in the medical surveillance of participants were a problem in
the second example [65]. Consequently, the authors provide more
detail about the additional data they collected to tackle this prob-
lem. When investigators have set up quality control programs for
data collection to counter a possible “drift”in measurements of
variables in longitudinal studies, or to keep variability at aminimum
when multiple observers are used, these should be described.
Unfortunately, authors often do not address important biases
when reporting their results. Among 43 caseecontrol and cohort
studies published from 1990 to 1994 that investigated the risk of
second cancers in patients with a history of cancer, medical sur-
veillance bias was mentioned in only 5 articles [66]. A survey of
reports of mental health research published during 1998 in three
psychiatric journals found that only 13% of 392 articles mentioned
response bias [67]. A survey of cohort studies in stroke research
found that 14 of 49 (28%) articles published from 1999 to 2003
addressed potential selection bias in the recruitment of study
participants and 35 (71%)mentioned the possibility that any type of
bias may have affected results [5].
10. Study size: Explain how the study size was arrived at.
Example 1
“The number of cases in the area during the study period
determined the sample size” [73].
Example 2
“A survey of postnatal depression in the region haddocumented a
prevalence of 19.8%. Assuming depression in mothers with normal
weight children to be 20% and an odds ratio of 3 for depression in
mothers with a malnourished child we needed 72 caseecontrol sets
(onecase toonecontrol)withan80%powerand5%signiﬁcance” [74].
Explanation
A study should be large enough to obtain a point estimatewith a
sufﬁciently narrow conﬁdence interval to meaningfully answer a
research question. Large samples are needed to distinguish a small
association from no association. Small studies often provide valu-
able information, but wide conﬁdence intervals may indicate that
they contribute less to current knowledge in comparison with
studies providing estimates with narrower conﬁdence intervals.
Also, small studies that show ‘interesting’ or ‘statistically signiﬁ-
cant’ associations are published more frequently than small studies
that do not have ‘signiﬁcant’ ﬁndings. While these studies may
provide an early signal in the context of discovery, readers should
be informed of their potential weaknesses.
The importance of sample size determination in observational
studies depends on the context. If an analysis is performed on data
that were already available for other purposes, the main question is
whether the analysis of the datawill produce results with sufﬁcient
statistical precision to contribute substantially to the literature, and
sample size considerations will be informal. Formal, a priori
calculation of sample size may be useful when planning a new
study [75,76]. Such calculations are associated with more uncer-
tainty than implied by the single number that is generally pro-
duced. For example, estimates of the rate of the event of interest or
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other assumptions central to calculations are commonly imprecise,
if not guesswork [77]. The precision obtained in the ﬁnal analysis
can often not be determined beforehand because it will be reduced
by inclusion of confounding variables in multivariable analyses
[78], the degree of precision with which key variables can be
measured [79], and the exclusion of some individuals.
Few epidemiological studies explain or report deliberations
about sample size [4,5]. We encourage investigators to report
pertinent formal sample size calculations if they were done. In
other situations they should indicate the considerations that
determined the study size (e.g., a ﬁxed available sample, as in the
ﬁrst example above). If the observational study was stopped early
when statistical signiﬁcance was achieved, readers should be told.
Do not bother readers with post hoc justiﬁcations for study size or
retrospective power calculations [77]. From the point of view of the
reader, conﬁdence intervals indicate the statistical precision that
was ultimately obtained. It should be realized that conﬁdence in-
tervals reﬂect statistical uncertainty only, and not all uncertainty
that may be present in a study (see item 20).
11. Quantitative variables: Explain how quantitative variables
were handled in the analyses. If applicable, describe which
groupings were chosen, and why.
Example
“Patientswith a GlasgowComa Scale less than 8 are considered to
be seriously injured. A GCS of 9 or more indicates less serious brain
injury. We examined the association of GCS in these two categories
with the occurrence of death within 12 months from injury” [80].
Explanation
Investigators make choices regarding how to collect and analyse
quantitative data about exposures, effectmodiﬁers andconfounders.
For example, they may group a continuous exposure variable to
create a new categorical variable (see Box 4). Grouping choices may
have important consequences for later analyses [81,82]. We advise
that authors explain why and how they grouped quantitative data,
including the number of categories, the cut-points, and category
meanormedianvalues.Whenever data are reported in tabular form,
the counts of cases, controls, persons at risk, person-time at risk, etc.
should be given for each category. Tables should not consist solely of
effect-measure estimates or results of model ﬁtting.
Investigatorsmightmodel an exposure as continuous in order to
retain all the information. In making this choice, one needs to
consider the nature of the relationship of the exposure to the
outcome. As it may be wrong to assume a linear relation auto-
matically, possible departures from linearity should be investi-
gated. Authors could mention alternative models they explored
during analyses (e.g., using log transformation, quadratic terms or
spline functions). Several methods exist for ﬁtting a non-linear
relation between the exposure and outcome [82e84]. Also, it may
be informative to present both continuous and grouped analyses
for a quantitative exposure of prime interest.
In a recent survey, two thirds of epidemiological publications
studied quantitative exposure variables [4]. In 42 of 50 articles
(84%) exposures were grouped into several ordered categories, but
often without any stated rationale for the choices made. Fifteen
articles used linear associations to model continuous exposure but
only two reported checking for linearity. In another survey, of the
psychological literature, dichotomizationwas justiﬁed in only 22 of
110 articles (20%) [85].
12. Statistical methods:
12(a). Describe all statistical methods, including those used to
control for confounding
Example
“The adjusted relative risk was calculated using the Man-
telHaenszel technique, when evaluating if confounding by age or
gender was present in the groups compared. The 95% conﬁdence in-
terval (CI) was computed around the adjusted relative risk, using the
variance according to Greenland and Robins and Robins et al.” [93].
Explanation
In general, there is no one correct statistical analysis but, rather,
several possibilities that may address the same question, but make
different assumptions. Regardless, investigators should pre-
determine analyses at least for the primary study objectives in a
study protocol. Often additional analyses are needed, either instead
of, or as well as, those originally envisaged, and these may some-
times be motivated by the data. When a study is reported, authors
should tell readers whether particular analyses were suggested by
data inspection. Even though the distinction between pre-speciﬁed
and exploratory analyses may sometimes be blurred, authors
should clarify reasons for particular analyses.
If groups being compared are not similar with regard to some
characteristics, adjustment should be made for possible con-
founding variables by stratiﬁcation or by multivariable regression
(see Box 5) [94]. Often, the study design determines which type of
regression analysis is chosen. For instance, Cox proportional hazard
regression is commonly used in cohort studies [95] whereas logistic
regression is often the method of choice in caseecontrol studies
[96,97]. Analysts should fully describe speciﬁc procedures for var-
iable selection and not only present results from the ﬁnal model
[98,99]. If model comparisons are made to narrow down a list of
potential confounders for inclusion in a ﬁnal model, this process
should be described. It is helpful to tell readers if one or two
covariates are responsible for a great deal of the apparent con-
founding in a data analysis. Other statistical analyses such as
imputation procedures, data transformation, and calculations of
attributable risks should also be described. Nonstandard or novel
approaches should be referenced and the statistical software used
reported. As a guiding principle, we advise statistical methods be
described “with enough detail to enable a knowledgeable reader
with access to the original data to verify the reported results” [100].
In an empirical study, only 93 of 169 articles (55%) reporting
adjustment for confounding clearly stated how continuous and
multi-category variables were entered into the statistical model
[101]. Another study found that among 67 articles in which sta-
tistical analyses were adjusted for confounders, it was mostly un-
clear how confounders were chosen [4].
12(b). Describe any methods used to examine subgroups and
interactions.
Example
“Sex differences in susceptibility to the 3 lifestyle-related risk
factors studied were explored by testing for biological interaction
according to Rothman: a new composite variable with 4 categories
(a-b-, a-bþ, aþb-, and aþbþ) was redeﬁned for sex and a dichotomous
exposure of interest where a- and b- denote absence of exposure. RR
was calculated for each category after adjustment for age. An
interaction effect is deﬁned as departure from additivity of absolute
effects, and excess RR caused by interaction (RERI) was calculated:
RERI ¼ RRðaþbþÞ  RRðabþÞ  RRðaþbÞ þ 1
where RR(aþbþ) denotes RR among those exposed to both factors
where RR(a-b-) is used as reference category (RR ¼ 1.0). Ninety-ﬁve
percent CIs were calculated as proposed by Hosmer and Lemeshow.
RERI of 0 means no interaction” [103].
Explanation
As discussed in detail under item 17, many debate the use and
value of analyses restricted to subgroups of the study population
[4,104]. Subgroup analyses are nevertheless often done [4]. Readers
J.P. Vandenbroucke et al. / International Journal of Surgery 12 (2014) 1500e1524 1511
need to know which subgroup analyses were planned in advance,
and which arose while analysing the data. Also, it is important to
explain what methods were used to examine whether effects or
associations differed across groups (see item 17).
Interaction relates to the situationwhen one factor modiﬁes the
effect of another (therefore also called ‘effect modiﬁcation’). The
joint action of two factors can be characterized in two ways: on an
additive scale, in terms of risk differences; or on a multiplicative
scale, in terms of relative risk (see Box 8). Many authors and readers
may have their own preference about the way interactions should
be analysed. Still, they may be interested to know to what extent
the joint effect of exposures differs from the separate effects. There
is consensus that the additive scale, which uses absolute risks, is
more appropriate for public health and clinical decision making
[105]. Whatever view is taken, this should be clearly presented to
the reader, as is done in the example above [103]. A lay-out pre-
senting separate effects of both exposures as well as their joint
effect, each relative to no exposure, might be most informative. It is
presented in the example for interaction under item 17, and the
calculations on the different scales are explained in Box 8.
12(c). Explain how missing data were addressed.
Example
“Our missing data analysis procedures used missing at random
(MAR) assumptions. We used the MICE (multivariate imputation by
chained equations) method of multiple multivariate imputation in
STATA. We independently analysed 10 copies of the data, each with
missing values suitably imputed, in themultivariate logistic regression
analyses. We averaged estimates of the variables to give a single mean
estimateandadjustedstandarderrorsaccording toRubin's rules” [106].
Explanation
Missing data are common in observational research. Question-
nairesposted to studyparticipantsarenot alwaysﬁlled incompletely,
participants may not attend all follow-up visits and routine data
sources and clinical databases are often incomplete. Despite its
ubiquity and importance, few papers report in detail on the problem
of missing data [5,107]. Investigators may use any of several ap-
proaches to address missing data. We describe some strengths and
limitations of various approaches in Box 6. We advise that authors
report the number of missing values for each variable of interest
(exposures, outcomes, confounders) and for each step in the analysis.
Authors should give reasons for missing values if possible, and indi-
cate how many individuals were excluded because of missing data
when describing the ﬂow of participants through the study (see also
item 13). For analyses that account for missing data, authors should
describe the nature of the analysis (e.g., multiple imputation) and the
assumptions that were made (e.g., missing at random, see Box 6).
12(d). Cohort study: If applicable, describe how loss to follow-up
was addressed.
Example
“In treatment programmes with active follow-up, those lost to
follow-up and those followed-up at 1 year had similar baseline CD4
cell counts (median 115 cells per mL and 123 cells per mL), whereas
patients lost to follow-up in programmes with no active follow-up
procedures had considerably lower CD4 cell counts than those
followed-up (median 64 cells per mL and 123 cells per mL). (…)
Treatment programmes with passive follow-up were excluded
from subsequent analyses” [116].
Explanation
Cohort studies are analysed using life table methods or other
approaches that are based on the person-time of follow-up and time
to developing the disease of interest. Among individuals who
remain free of the disease at the end of their observation period, the
amount of follow-up time is assumed to be unrelated to the prob-
ability of developing the outcome. This will be the case if follow-up
ends on a ﬁxed date or at a particular age. Loss to follow-up occurs
when participants withdraw from a study before that date. This may
hamper the validity of a study if loss to follow-up occurs selectively
in exposed individuals, or in persons at high risk of developing the
disease (‘informative censoring’). In the example above, patients lost
to follow-up in treatment programmes with no active follow-up had
fewer CD4 helper cells than those remaining under observation and
were therefore at higher risk of dying [116].
It is important todistinguishpersonswhoreachtheendof thestudy
from those lost to follow-up. Unfortunately, statistical software usually
does not distinguish between the two situations: in both cases follow-
up time is automatically truncated (‘censored’) at the end of the
observationperiod. Investigators thereforeneedtodecide, ideallyat the
stage of planning the study, how they will deal with loss to follow-up.
When few patients are lost, investigators may either exclude
individuals with incomplete follow-up, or treat them as if they
withdrew alive at either the date of loss to follow-up or the end of
the study.We advise authors to report howmany patients were lost
to follow-up and what censoring strategies they used.
12(d). Caseecontrol study: If applicable, explain how matching
of cases and controls was addressed.
Example
“We used McNemar's test, paired t test, and conditional logistic
regression analysis to compare dementia patients with their
matched controls for cardiovascular risk factors, the occurrence of
spontaneous cerebral emboli, carotid disease, and venous to arte-
rial circulation shunt” [117].
Explanation
In individually matched caseecontrol studies a crude analysis of
the odds ratio, ignoring the matching, usually leads to an estimation
that is biased towards unity (see Box 2). A matched analysis is there-
fore often necessary. This can intuitively be understood as a stratiﬁed
analysis: each case is seen as one stratum with his or her set of
matched controls. The analysis rests on considering whether the case
is more often exposed than the controls, despite having made them
alike regarding the matching variables. Investigators can do such a
stratiﬁedanalysis using theMantel-Haenszelmethodona ‘matched’2
by2 table. In its simplest form theodds ratio becomes the ratio of pairs
that are discordant for the exposure variable. Ifmatchingwasdone for
variables like age and sex that are universal attributes, the analysis
needs not retain the individual, person-to-personmatching: a simple
analysis in categories of age and sex is sufﬁcient [50]. For other
matching variables, such as neighbourhood, sibship, or friendship,
however, each matched set should be considered its own stratum.
In individually matched studies, the most widely used method
of analysis is conditional logistic regression, in which each case and
their controls are considered together. The conditional method is
necessary when the number of controls varies among cases, and
when, in addition to thematching variables, other variables need to
be adjusted for. To allow readers to judge whether the matched
design was appropriately taken into account in the analysis, we
recommend that authors describe in detail what statistical
methods were used to analyse the data. If taking the matching into
account does have little effect on the estimates, authorsmay choose
to present an unmatched analysis.
12(d). Cross-sectional study: If applicable, describe analytical
methods taking account of sampling strategy.
Example
“The standard errors (SE) were calculated using the Taylor
expansion method to estimate the sampling errors of estimators
based on the complex sample design. (…) The overall design effect
for diastolic blood pressure was found to be 1.9 for men and 1.8 for
women and, for systolic blood pressure, it was 1.9 for men and 2.0
for women” [118].
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Explanation
Most cross-sectional studies use a pre-speciﬁed sampling
strategy to select participants from a source population.
Sampling may be more complex than taking a simple random
sample, however. It may include several stages and clustering of
participants (e.g., in districts or villages). Proportionate stratiﬁca-
tion may ensure that subgroups with a speciﬁc characteristic are
correctly represented. Disproportionate stratiﬁcationmay be useful
to over-sample a subgroup of particular interest.
An estimate of association derived from a complex sample may
be more or less precise than that derived from a simple random
sample. Measures of precision such as standard error or conﬁdence
interval should be corrected using the design effect, a ratio measure
that describes how much precision is gained or lost if a more
complex sampling strategy is used instead of simple random
sampling [119]. Most complex sampling techniques lead to a
decrease of precision, resulting in a design effect greater than 1.
We advise that authors clearly state the method used to adjust
for complex sampling strategies so that readers may understand
how the chosen sampling method inﬂuenced the precision of the
obtained estimates. For instance, with clustered sampling, the im-
plicit trade-off between easier data collection and loss of precision is
transparent if the design effect is reported. In the example, the
calculated design effects of 1.9 for men indicates that the actual
sample size would need to be 1.9 times greater than with simple
random sampling for the resulting estimates to have equal precision.
12(e). Describe any sensitivity analyses.
Example
“Because we had a relatively higher proportion of ‘missing’ dead
patients with insufﬁcient data (38/148¼ 25.7%) as compared to live
patients (15/437 ¼ 3.4%) (…), it is possible that this might have
biased the results. We have, therefore, carried out a sensitivity
analysis. We have assumed that the proportion of women using
oral contraceptives in the study group applies to the whole (19.1%
for dead, and 11.4% for live patients), and then applied two extreme
scenarios: either all the exposed missing patients used second
generation pills or they all used third-generation pills” [120].
Explanation
Sensitivity analyses are useful to investigate whether or not the
main results are consistent with those obtained with alternative
analysis strategies or assumptions [121]. Issues that may be
examined include the criteria for inclusion in analyses, the deﬁni-
tions of exposures or outcomes [122], which confounding variables
merit adjustment, the handling of missing data [120,123], possible
selection bias or bias from inaccurate or inconsistent measurement
of exposure, disease and other variables, and speciﬁc analysis
choices, such as the treatment of quantitative variables (see item
11). Sophisticated methods are increasingly used to simultaneously
model the inﬂuence of several biases or assumptions [124e126].
In 1959 Cornﬁeld et al. famously showed that a relative risk of 9
for cigarette smoking and lung cancer was extremely unlikely to be
due to any conceivable confounder, since the confounder would
need to be at least nine times as prevalent in smokers as in non-
smokers [127]. This analysis did not rule out the possibility that
such a factor was present, but it did identify the prevalence such a
factor would need to have. The same approach was recently used to
identify plausible confounding factors that could explain the as-
sociation between childhood leukaemia and living near electric
power lines [128]. More generally, sensitivity analyses can be used
to identify the degree of confounding, selection bias, or information
bias required to distort an association. One important, perhaps
under recognised, use of sensitivity analysis is when a study shows
little or no association between an exposure and an outcome and it
is plausible that confounding or other biases toward the null are
present.
2.4. Results
The Results section should give a factual account of what was
found, from the recruitment of study participants, the description
of the study population to themain results and ancillary analyses. It
should be free of interpretations and discursive text reﬂecting the
authors' views and opinions.
13. Participants:
13(a). Report the numbers of individuals at each stage of the
studyde.g., numbers potentially eligible, examined for eligibility,
conﬁrmed eligible, included in the study, completing follow-up,
and analysed.
Example
“Of the 105 freestanding bars and taverns sampled, 13 estab-
lishments were no longer in business and 9 were located in res-
taurants, leaving 83 eligible businesses. In 22 cases, the owner
could not be reached by telephone despite 6 or more attempts. The
owners of 36 bars declined study participation. (…) The 25
participating bars and taverns employed 124 bartenders, with 67
bartenders working at least 1 weekly daytime shift. Fifty-four of the
daytime bartenders (81%) completed baseline interviews and
spirometry; 53 of these subjects (98%) completed follow-up” [129].
Explanation
Detailed information on the process of recruiting study partici-
pants is important for several reasons. Those included in a study
often differ in relevant ways from the target population to which
results are applied. This may result in estimates of prevalence or
incidence that do not reﬂect the experience of the target population.
For example, people who agreed to participate in a postal survey of
sexual behaviour attended church less often, had less conservative
sexual attitudes and earlier age at ﬁrst sexual intercourse, and were
more likely to smoke cigarettes and drink alcohol than people who
refused [130]. These differences suggest that postal surveys may
overestimate sexual liberalism and activity in the population. Such
responsebias (seeBox3) candistortexposure-disease associations if
associations differ between those eligible for the study and those
included in the study. As another example, the association between
young maternal age and leukaemia in offspring, which has been
observed in some caseecontrol studies [131,132], was explained by
differential participation of young women in case and control
groups. Young women with healthy children were less likely to
participate than those with unhealthy children [133]. Although low
participation does not necessarily compromise the validity of a
study, transparent informationonparticipationandreasons fornon-
participation is essential. Also, as there are no universally agreed
deﬁnitions for participation, response or follow-up rates, readers
need to understand how authors calculated such proportions [134].
Ideally, investigators should give an account of the numbers of
individuals considered at each stage of recruiting study partici-
pants, from the choice of a target population to the inclusion of
participants' data in the analysis. Depending on the type of study,
this may include the number of individuals considered to be
potentially eligible, the number assessed for eligibility, the number
found to be eligible, the number included in the study, the number
examined, the number followed-up and the number included in
the analysis. Information on different sampling units may be
required, if sampling of study participants is carried out in two or
more stages as in the example above (multistage sampling). In
caseecontrol studies, we advise that authors describe the ﬂow of
participants separately for case and control groups [135]. Controls
can sometimes be selected from several sources, including, for
example, hospitalised patients and community dwellers. In this
case, we recommend a separate account of the numbers of
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participants for each type of control group. Olson and colleagues
proposed useful reporting guidelines for controls recruited through
random-digit dialling and other methods [136].
A recent survey of epidemiological studies published in 10 gen-
eral epidemiology, public health and medical journals found that
some information regarding participation was provided in 47 of 107
caseecontrol studies (59%), 49 of 154 cohort studies (32%), and 51 of
86 cross-sectional studies (59%) [137]. Incomplete or absent
reporting of participation and non-participation in epidemiological
studies was also documented in two other surveys of the literature
[4,5]. Finally, there is evidence that participation in epidemiological
studies may have declined in recent decades [137,138], which un-
derscores the need for transparent reporting [139].
13(b). Give reasons for non-participation at each stage
Example
“Themain reasons for non-participationwere the participantwas
too ill or had died before interview (cases 30%, controls < 1%), non-
response (cases 2%, controls 21%), refusal (cases 10%, controls 29%),
and other reasons (refusal by consultant or general practitioner, non-
English speaking, mental impairment) (cases 7%, controls 5%)” [140].
Explanation
Explaining the reasons why people no longer participated in a
study or why they were excluded from statistical analyses helps
readers judge whether the study population was representative of
the target population andwhether biaswas possibly introduced. For
example, in a cross-sectional health survey, non-participationdue to
reasonsunlikely to be related tohealth status (for example, the letter
of invitationwas not delivered because of an incorrect address) will
affect theprecision of estimates butwill probablynot introduce bias.
Conversely, if many individuals opt out of the survey because of
illness, or perceived good health, results may underestimate or
overestimate the prevalence of ill health in the population.
13(c). Consider use of a ﬂow diagram.
Example
Flow diagram from Hay et al. [141].
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Explanation
An informative and well-structured ﬂow diagram can readily
and transparently convey information that might otherwise require
a lengthy description [142], as in the example above. The diagram
may usefully include themain results, such as the number of events
for the primary outcome. While we recommend the use of a ﬂow
diagram, particularly for complex observational studies, we do not
propose a speciﬁc format for the diagram.
14. Descriptive data:
14(a). Give characteristics of study participants (e.g., de-
mographic, clinical, social) and information on exposures and po-
tential confounders.
Example
Explanation
Readers need descriptions of study participants and their ex-
posures to judge the generalisability of the ﬁndings. Information
about potential confounders, including whether and how they
were measured, inﬂuences judgments about study validity. We
advise authors to summarize continuous variables for each study
group by giving the mean and standard deviation, or when the data
have an asymmetrical distribution, as is often the case, the median
and percentile range (e.g., 25th and 75th percentiles). Variables
that make up a small number of ordered categories (such as stages
of disease I to IV) should not be presented as continuous variables;
it is preferable to give numbers and proportions for each category
(see also Box 4). In studies that compare groups, the descriptive
characteristics and numbers should be given by group, as in the
example above.
Inferential measures such as standard errors and conﬁdence
intervals should not be used to describe the variability of charac-
teristics, and signiﬁcance tests should be avoided in descriptive
tables. Also, P values are not an appropriate criterion for selecting
which confounders to adjust for in analysis; even small differences
in a confounder that has a strong effect on the outcome can be
important [144,145].
In cohort studies, it may be useful to document how an
exposure relates to other characteristics and potential con-
founders. Authors could present this information in a table with
columns for participants in two or more exposure categories,
which permits to judge the differences in confounders between
these categories.
In caseecontrol studies potential confounders cannot be judged
by comparing cases and controls. Control persons represent the
source population and will usually be different from the cases in
many respects. For example, in a study of oral contraceptives and
myocardial infarction, a sample of young women with infarction
more often had risk factors for that disease, such as high serum
cholesterol, smoking and a positive family history, than the control
group [146]. This does not inﬂuence the assessment of the effect of
oral contraceptives, as long as the prescription of oral contracep-
tives was not guided by the presence of these risk factorsde.g.,
because the risk factors were only established after the event (see
also Box 5). In caseecontrol studies the equivalent of comparing
exposed and non-exposed for the presence of potential con-
founders (as is done in cohorts) can be achieved by exploring the
source population of the cases: if the control group is large enough
and represents the source population, exposed and unexposed
controls can be compared for potential confounders [121,147].
14(b). Indicate the number of participants with missing data for
each variable of interest.
Example
Explanation
As missing data may bias or affect generalisability of results,
authors should tell readers amounts of missing data for exposures,
potential confounders, and other important characteristics of pa-
tients (see also item 12c and Box 6). In a cohort study, authors
should report the extent of loss to follow-up (with reasons), since
incomplete follow-up may bias ﬁndings (see also items 12d and 13)
[148]. We advise authors to use their tables and ﬁgures to
enumerate amounts of missing data.
14(c). Cohort study: Summarise follow-up timede.g., average
and total amount
Example
“During the 4366 person-years of follow-up (median 5.4,
maximum 8.3 years), 265 subjects were diagnosed as having de-
mentia, including 202 with Alzheimer's disease” [149].
Explanation
Readers need to know the duration and extent of follow-up for
the available outcome data. Authors can present a summary of the
average follow-up with either the mean or median follow-up time
or both. The mean allows a reader to calculate the total number of
person-years by multiplying it with the number of study partici-
pants. Authors also may present minimum and maximum times or
percentiles of the distribution to show readers the spread of follow-
up times. They may report total person-years of follow-up or some
indication of the proportion of potential data that was captured
[148]. All such information may be presented separately for par-
ticipants in two or more exposure categories. Almost half of 132
articles in cancer journals (mostly cohort studies) did not give any
summary of length of follow-up [37].
15. Outcome data:
Cohort study: Report numbers of outcome events or summary
measures over time
Table.
Characteristics of the study base at enrolment, Castellana G (Italy), 1985e1986.
HCV-negative
n ¼ 1458
HCV-positive
n ¼ 511
Unknown
n ¼ 513
Sex (%)
Male 936 (64%) 296 (58%) 197 (39%)
Female 522 (36%) 215 (42%) 306 (61%)
Mean age at
enrolment
(SD)
45.7 (10.5) 52.0 (9.7) 52.5 (9.8)
Daily alcohol
intake (%)
None 250 (17%) 129 (25%) 119 (24%)
Moderatea 853 (59%) 272 (53%) 293 (58%)
Excessiveb 355 (24%) 110 (22%) 91 (18%)
HCV, Hepatitis C virus.
a Males < 60 g ethanol/day, females < 30 g ethanol/day.
b Males > 60 g ethanol/day, females > 30 g ethanol/day.
Table adapted from Osella et al. [143].
Table.
Symptom end points used in survival analysis.
Cough Short of breath Sleeplessness
Symptom resolved 201 (79%) 138 (54%) 171 (67%)
Censored 27 (10%) 21 (8%) 24 (9%)
Never symptomatic 0 46 (18%) 11 (4%)
Data missing 28 (11%) 51 (20%) 50 (20%)
Total 256 (100%) 256 (100%) 256 (100%)
Table adapted from Hay et al. [141].
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Example
Caseecontrol study: Report numbers in each exposure category,
or summary measures of exposure.
Example
Cross-sectional study: Report numbers of outcome events or
summary measures.
Example
Explanation
Before addressing the possible association between exposures
(risk factors) and outcomes, authors should report relevant
descriptive data. It may be possible and meaningful to present
measures of association in the same table that presents the
descriptive data (see item 14a). In a cohort study with events as
outcomes, report the numbers of events for each outcome of in-
terest. Consider reporting the event rate per person-year of follow-
up. If the risk of an event changes over follow-up time, present the
numbers and rates of events in appropriate intervals of follow-up or
as a KaplaneMeier life table or plot. It might be preferable to show
plots as cumulative incidence that go up from 0% rather than down
from 100%, especially if the event rate is lower than, say, 30% [153].
Consider presenting such information separately for participants in
different exposure categories of interest. If a cohort study is
investigating other time-related outcomes (e.g., quantitative dis-
ease markers such as blood pressure), present appropriate sum-
mary measures (e.g., means and standard deviations) over time,
perhaps in a table or ﬁgure.
For cross-sectional studies, we recommend presenting the same
type of information on prevalent outcome events or summary
measures. For caseecontrol studies, the focus will be on reporting
exposures separately for cases and controls as frequencies or
quantitative summaries [154]. For all designs, it may be helpful also
to tabulate continuous outcomes or exposures in categories, even if
the data are not analysed as such.
16. Main results:
16(a). Give unadjusted estimates and, if applicable,
confounder-adjusted estimates and their precision (e.g.,
95% conﬁdence intervals). Make clear which confounders
were adjusted for and why they were included.
Example 1
“We initially considered the following variables as potential
confounders by Mantel-Haenszel stratiﬁed analysis: (…) The vari-
ables we included in the ﬁnal logistic regression models were those
(…) that produced a 10% change in the odds ratio after the Mantel-
Haenszel adjustment” [155].
Example 2
Table.
Rates of HIV-1 seroconversion by selected sociodemographic variables: 1990e1993.
Variable Person-years No.
seroconverted
Rate/1000 person-
years (95% CI)
Calendar year
1990 2197.5 18 8.2 (4.4e12.0)
1991 3210.7 22 6.9 (4.0e9.7)
1992 3162.6 18 5.7 (3.1e8.3)
1993 2912.9 26 8.9 (5.5e12.4)
1994 1104.5 5 4.5 (0.6e8.5)
Tribe
Bagandan 8433.1 48 5.7 (4.1e7.3)
Other Ugandan 578.4 9 15.6 (5.4e25.7)
Rwandese 2318.6 16 6.9 (3.5e10.3)
Other tribe 866.0 12 13.9 (6.0e21.7)
Religion
Muslim 3313.5 9 2.7 (0.9e4.5)
Other 8882.7 76 8.6 (6.6e10.5)
CI, conﬁdence interval.
Table adapted from Kengeya-Kayondo et al. [150].
Table.
Exposure among liver cirrhosis cases and controls
Cases (n ¼ 40) Controls (n ¼ 139)
Vinyl chloride monomer (cumulative exposure: ppm  years)
<160 7 (18%) 38 (27%)
160e500 7 (18%) 40 (29%)
500e2500 9 (23%) 37 (27%)
>2500 17 (43%) 24 (17%)
Alcohol consumption (g/day)
<30 1 (3%) 82 (59%)
30e60 7 (18%) 46 (33%)
>60 32 (80%) 11 (8%)
HBsAG/HCV
Negative 33 (83%) 136 (98%)
Positive 7 (18%) 3 (2%)
HBsAG, hepatitis B surface antigen; HCV, hepatitis C virus.
Table adapted from Mastrangelo et al. [151].
Table.
Prevalence of current asthma and Diagnosed Hay fever by average alternaria alter-
nata antigen level in the household
Categorized
Alternaria Levela
Current asthma Diagnosed Hay fever
N Prevalenceb (95% CI) N Prevalenceb(95% CI)
1st tertile 40 4.8 (3.3e6.9) 93 16.4 (13.0e20.5)
2nd tertile 61 7.5 (5.2e10.6) 122 17.1 (12.8e22.5)
3rd tertile 73 8.7 (6.7e11.3) 93 15.2 (12.1e18.9)
a 1st tertile < 3.90 mg/g; 2nd tertile 3.90e6.27 mg/g; 3rd tertile  6.28 mg/g.
b Percentage (95% CI) weighted for themultistage sampling design of the National
Survey of Lead and Allergens in Housing.
Table adapted from Salo et al. [152].
Table.
Relative rates of rehospitalisation by treatment in patients in community care after
ﬁrst hospitalisation due to schizophrenia and schizoaffective disorder
Treatment No. of
person
Relapses
years
Crude
relative
rate
(95% CI)
Adjusted
relative
rate
(95% CI)
Fully
adjusted
relative rate
(95% CI)
Perphenazine 53 187 0.41 0.45 0.32
(0.29 to 0.59) (0.32 to 0.65) (0.22 to 0.49)
Olanzapine 329 822 0.59 0.55 0.54
(0.45 to 0.75) (0.43 to 0.72) (0.41 to 0.71)
Clozapine 336 804 0.61 0.53 0.64
(0.47 to 0.79) (0.41 to 0.69) (0.48 to 0.85)
Chlorprothixene 79 146 0.79 0.83 0.64
(0.58 to 1.09) (0.61 to 1.15) (0.45 to 0.91)
Thioridazine 115 201 0.84 0.82 0.70
(0.63 to 1.12) (0.61 to 1.10) (0.51 to 0.96)
Perphenazine 155 327 0.69 0.78 0.85
(0.58 to 0.82) (0.59 to 1.03) (0.63 to 1.13)
Risperidone 343 651 0.77 0.80 0.89
(0.60 to 0.99) (0.62 to 1.03) (0.69 to 1.16)
Haloperidol 73 107 1.00 1.00 1.00
Chlorpromazine 82 127 0.94 0.97 1.06
(0.69 to 1.29) (0.71 to 1.33) (0.76 to 1.47)
Levomepromazine 52 63 1.21 0.82 1.09
(0.84 to 1.73) (0.58 to 1.18) (0.76 to 1.57)
No antipsychotic
drugs
2248 3362 0.98 1.01 1.16
(0.77 to 1.23) (0.80 to 1.27) (0.91 to 1.47)
Adjusted for sex, calendar year, age at onset of follow-up, number of previous re-
lapses, duration of ﬁrst hospitalisation, and length of follow-up (adjusted column)
and additionally for a score of the propensity to start a treatment other than halo-
peridol (fully adjusted column).
Table adapted from Tiihonen et al. [156].
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Explanation
In many situations, authors may present the results of unad-
justed orminimally adjusted analyses and those from fully adjusted
analyses. We advise giving the unadjusted analyses together with
the main data, for example the number of cases and controls that
were exposed or not. This allows the reader to understand the data
behind the measures of association (see also item 15). For adjusted
analyses, report the number of persons in the analysis, as this
number may differ because of missing values in covariates (see also
item 12c). Estimates should be given with conﬁdence intervals.
Readers can compare unadjusted measures of association with
those adjusted for potential confounders and judge by how much,
and in what direction, they changed. Readers may think that
‘adjusted’ results equal the causal part of the measure of associa-
tion, but adjusted results are not necessarily free of random sam-
pling error, selection bias, information bias, or residual confounding
(see Box 5). Thus, great care should be exercised when interpreting
adjusted results, as the validity of results often depends crucially on
complete knowledge of important confounders, their precise
measurement, and appropriate speciﬁcation in the statistical model
(see also item 20) [157,158].
Authors should explain all potential confounders considered,
and the criteria for excluding or including variables in statistical
models. Decisions about excluding or including variables should be
guided by knowledge, or explicit assumptions, on causal relations.
Inappropriate decisions may introduce bias, for example by
including variables that are in the causal pathway between expo-
sure and disease (unless the aim is to asses how much of the effect
is carried by the intermediary variable). If the decision to include a
variable in the model was based on the change in the estimate, it is
important to report what change was considered sufﬁciently
important to justify its inclusion. If a ‘backward deletion’ or ‘for-
ward inclusion’ strategy was used to select confounders, explain
that process and give the signiﬁcance level for rejecting the null
hypothesis of no confounding. Of note, we and others do not advise
selecting confounders based solely on statistical signiﬁcance
testing [147,159,160].
Recent studies of the quality of reporting of epidemiological
studies found that conﬁdence intervals were reported in most ar-
ticles [4]. However, few authors explained their choice of con-
founding variables [4,5].
16(b). Report category boundaries when continuous variables
were categorised
Example
Explanation
Categorizing continuous data has several important implica-
tions for analysis (see Box 4) and also affects the presentation of
results. In tables, outcomes should be given for each exposure
category, for example as counts of persons at risk, person-time at
risk, if relevant separately for each group (e.g., cases and controls).
Details of the categories used may aid comparison of studies and
meta-analysis. If data were grouped using conventional cut-points,
such as body mass index thresholds [162], group boundaries (i.e.,
range of values) can be derived easily, except for the highest and
lowest categories. If quantile-derived categories are used, the
category boundaries cannot be inferred from the data. As a mini-
mum, authors should report the category boundaries; it is helpful
also to report the range of the data and the mean or median values
within categories.
16(c). If relevant, consider translating estimates of relative risk
into absolute risk for a meaningful time period.
Example
“10 years' use of HRT [hormone-replacement therapy] is esti-
mated to result in ﬁve (95% CI 3e7) additional breast cancers per
1000 users of oestrogen-only preparations and 19 (15e23) addi-
tional cancers per 1000 users of oestrogenprogestagen combina-
tions” [163].
Explanation
The results from studies examining the association between an
exposure and a disease are commonly reported in relative terms, as
ratios of risks, rates or odds (see Box 8). Relative measures capture
the strength of the association between an exposure and disease. If
the relative risk is a long way from 1 it is less likely that the asso-
ciation is due to confounding [164,165]. Relative effects or associ-
ations tend to be more consistent across studies and populations
than absolute measures, but what often tends to be the case may be
irrelevant in a particular instance. For example, similar relative
risks were obtained for the classic cardiovascular risk factors for
men living in Northern Ireland, France, the USA and Germany,
despite the fact that the underlying risk of coronary heart disease
varies substantially between these countries [166,167]. In contrast,
in a study of hypertension as a risk factor for cardiovascular disease
mortality, the data were more compatible with a constant rate
difference than with a constant rate ratio [168].
Widely used statistical models, including logistic [169] and
proportional hazards (Cox) regression [170] are based on ratio
measures. In these models, only departures from constancy of ratio
effect measures are easily discerned. Nevertheless, measures which
assess departures from additivity of risk differences, such as the
Relative Excess Risk from Interaction (RERI, see item 12b and Box
8), can be estimated in models based on ratio measures.
In many circumstances, the absolute risk associated with an
exposure is of greater interest than the relative risk. For example, if
the focus is on adverse effects of a drug, one will want to know the
number of additional cases per unit time of use (e.g., days, weeks, or
years). The example gives the additional number of breast cancer
cases per 1000 women who used hormone-replacement therapy
for 10 years [163]. Measures such as the attributable risk or popu-
lation attributable fraction may be useful to gauge how much dis-
ease can be prevented if the exposure is eliminated. They should
preferably be presented together with a measure of statistical un-
certainty (e.g., conﬁdence intervals as in the example). Authors
should be aware of the strong assumptions made in this context,
including a causal relationship between a risk factor and disease
(also see Box 7) [171]. Because of the semantic ambiguity and
complexities involved, authors should report in detail what
methods were used to calculate attributable risks, ideally giving the
formulae used [172].
A recent survey of abstracts of 222 articles published in leading
medical journals found that in 62% of abstracts of randomised trials
including a ratio measure absolute risks were given, but only in 21%
of abstracts of cohort studies [173]. A free text search of Medline
1966 to 1997 showed that 619 itemsmentioned attributable risks in
the title or abstract, compared to 18,955 using relative risk or odds
ratio, for a ratio of 1 to 31 [174].
17. Other analyses: Report other analyses donede.g., analyses of
subgroups and interactions, and sensitivity analyses.
Table.
Polychlorinated biphenyls in cord serum.
Quartile Range (ng/g) Number
1 0.07e0.24 180
2 0.24e0.38 181
3 0.38e0.60 181
4 0.61e18.14 180
Table adapted from Sagiv et al. [161].
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Example 1
Example 2
Explanation
In addition to the main analysis other analyses are often done in
observational studies. They may address speciﬁc subgroups, the
potential interaction between risk factors, the calculation of
attributable risks, or use alternative deﬁnitions of study variables in
sensitivity analyses.
There is debate about the dangers associated with subgroup
analyses, and multiplicity of analyses in general [4,104]. In our
opinion, there is too great a tendency to look for evidence of
subgroup-speciﬁc associations, or effect-measure modiﬁcation,
when overall results appear to suggest little or no effect. On the
other hand, there is value in exploring whether an overall associ-
ation appears consistent across several, preferably pre-speciﬁed
subgroups especially when a study is large enough to have sufﬁ-
cient data in each subgroup. A second area of debate is about
interesting subgroups that arose during the data analysis. They
might be important ﬁndings, but might also arise by chance. Some
argue that it is neither possible nor necessary to inform the reader
about all subgroup analyses done as future analyses of other data
will tell to what extent the early exciting ﬁndings stand the test of
time [9]. We advise authors to report which analyses were planned,
and which were not (see also items 4, 12b and 20). This will allow
readers to judge the implications of multiplicity, taking into ac-
count the study's position on the continuum from discovery to
veriﬁcation or refutation.
A third area of debate is how joint effects and interactions be-
tween risk factors should be evaluated: on additive or
multiplicative scales, or should the scale be determined by the
statistical model that ﬁts best (see also item 12b and Box 8)? A
sensible approach is to report the separate effect of each exposure
as well as the joint effectdif possible in a table, as in the ﬁrst
example above [183], or in the study by Martinelli et al. [185]. Such
a table gives the reader sufﬁcient information to evaluate additive
as well as multiplicative interaction (how these calculations are
done is shown in Box 8). Conﬁdence intervals for separate and joint
effects may help the reader to judge the strength of the data. In
addition, conﬁdence intervals around measures of interaction, such
as the Relative Excess Risk from Interaction (RERI) relate to tests of
interaction or homogeneity tests. One recurrent problem is that
authors use comparisons of P values across subgroups, which lead
to erroneous claims about an effect modiﬁer. For instance, a sta-
tistically signiﬁcant association in one category (e.g., men), but not
in the other (e.g., women) does not in itself provide evidence of
effect modiﬁcation. Similarly, the conﬁdence intervals for each
point estimate are sometimes inappropriately used to infer that
there is no interaction when intervals overlap. A more valid infer-
ence is achieved by directly evaluating whether the magnitude of
an association differs across subgroups.
Sensitivity analyses are helpful to investigate the inﬂuence of
choices made in the statistical analysis, or to investigate the
robustness of the ﬁndings to missing data or possible biases (see
also item 12b). Judgement is needed regarding the level of
reporting of such analyses. If many sensitivity analyses were per-
formed, it may be impractical to present detailed ﬁndings for them
all. It may sometimes be sufﬁcient to report that sensitivity analyses
were carried out and that they were consistent with the main re-
sults presented. Detailed presentation is more appropriate if the
issue investigated is of major concern, or if effect estimates vary
considerably [59,186].
Pocock and colleagues found that 43 out of 73 articles reporting
observational studies contained subgroup analyses. The majority
claimed differences across groups but only eight articles reported a
formal evaluation of interaction (see item 12b) [4].
2.5. Discussion
The discussion section addresses the central issues of validity
andmeaning of the study [191]. Surveys have found that discussion
sections are often dominated by incomplete or biased assessments
of the study's results and their implications, and rhetoric sup-
porting the authors' ﬁndings [192,193]. Structuring the discussion
may help authors avoid unwarranted speculation and over-
interpretation of results while guiding readers through the text
[194,195]. For example, Annals of Internal Medicine [196] recom-
mends that authors structure the discussion section by presenting
the following: (1) a brief synopsis of the key ﬁndings; (2) consid-
eration of possible mechanisms and explanations; (3) comparison
with relevant ﬁndings from other published studies; (4) limitations
of the study; and (5) a brief section that summarizes the implica-
tions of the work for practice and research. Others have made
similar suggestions [191,194]. The section on research recommen-
dations and the section on limitations of the study should be closely
linked to each other. Investigators should suggest ways in which
subsequent research can improve on their studies rather than
blandly stating ‘more research is needed’ [197,198]. We recommend
that authors structure their discussion sections, perhaps also using
suitable subheadings.
18. Key results: Summarise key results with reference to study
objectives.
Table.
Analysis of oral contraceptive use, presence of factor V Leiden Allele, and risk for
venous thromboembolism
Factor V
Leiden
Oral
contraceptives
No. of
patients
No. of
controls
Odds ratio
Yes Yes 25 2 34.7
Yes No 10 4 6.9
No Yes 84 63 3.7
No No 36 100 1 (Reference)
Table modiﬁed from Vandenbroucke et al. [182] by Botto et al. [183].
Table.
Sensitivity of the rate ratio for cardiovascular outcome to an unmeasured
confounder
Prevalence of
unmeasured
binary confounder
in the exposed
group, %
Prevalence of
unmeasured
binary confounder
in the comparator
group, %
Unmeasured
binary
confounder
rate ratio
High exposure
rate ratio
(95% CI)a
90 10 1.5 1.20 (1.01e1.42)
90 50 1.5 1.43 (1.22e1.67)
50 10 1.5 1.39 (1.18e1.63)
90 10 2 0.96 (0.81e1.13)
90 50 2 1.27 (1.11e1.45)
50 10 2 1.21 (1.03e1.42)
90 50 3 1.18 (1.01e1.38)
50 10 3 0.99 (0.85e1.16)
90 50 5 1.08 (0.85e1.26)
CI, conﬁdence interval.
a Adjusted for age, sex, cardiovascular drug use, and unmeasured binary
confounder.
Table adapted from Wei et al. [184].
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Example
“We hypothesized that ethnic minority status would be asso-
ciated with higher levels of cardiovascular disease (CVD) risk fac-
tors, but that the associations would be explained substantially by
socioeconomic status (SES). Our hypothesis was not conﬁrmed.
After adjustment for age and SES, highly signiﬁcant differences in
body mass index, blood pressure, diabetes, and physical inactivity
remained between white women and both black and Mexican
American women. In addition, we found large differences in CVD
risk factors by SES, a ﬁnding that illustrates the high-risk status of
both ethnic minority women aswell as whitewomenwith low SES”
[199].
Explanation
It is good practice to begin the discussion with a short summary
of the main ﬁndings of the study. The short summary reminds
readers of themain ﬁndings andmay help them assess whether the
subsequent interpretation and implications offered by the authors
are supported by the ﬁndings.
19. Limitations: Discuss limitations of the study, taking into ac-
count sources of potential bias or imprecision. Discuss both
direction and magnitude of any potential bias.
Example
“Since the prevalence of counselling increases with increasing
levels of obesity, our estimates may overestimate the true preva-
lence. Telephone surveys also may overestimate the true preva-
lence of counselling. Although persons without telephones have
similar levels of overweight as persons with telephones, persons
without telephones tend to be less educated, a factor associated
with lower levels of counselling in our study. Also, of concern is the
potential bias caused by those who refused to participate as well as
those who refused to respond to questions about weight. Further-
more, because data were collected cross-sectionally, we cannot
infer that counselling preceded a patient's attempt to lose weight”
[200].
Explanation
The identiﬁcation and discussion of the limitations of a study are
an essential part of scientiﬁc reporting. It is important not only to
identify the sources of bias and confounding that could have
affected results, but also to discuss the relative importance of
different biases, including the likely direction andmagnitude of any
potential bias (see also item 9 and Box 3).
Authors should also discuss any imprecision of the results.
Imprecision may arise in connection with several aspects of a
study, including the study size (item 10) and the measurement of
exposures, confounders and outcomes (item 8). The inability to
precisely measure true values of an exposure tends to result in
bias towards unity: the less precisely a risk factor is measured, the
greater the bias. This effect has been described as ‘attenuation’
[201,202], or more recently as ‘regression dilution bias’ [203].
However, when correlated risk factors are measured with
different degrees of imprecision, the adjusted relative risk asso-
ciated with them can be biased towards or away from unity
[204e206].
When discussing limitations, authors may compare the study
being presented with other studies in the literature in terms of
validity, generalisability and precision. In this approach, each study
can be viewed as contribution to the literature, not as a stand-alone
basis for inference and action [207]. Surprisingly, the discussion of
important limitations of a study is sometimes omitted from pub-
lished reports. A survey of authors who had published original
research articles in The Lancet found that important weaknesses of
the study were reported by the investigators in the survey ques-
tionnaires, but not in the published article [192].
20. Interpretation: Give a cautious overall interpretation
considering objectives, limitations, multiplicity of analyses,
results from similar studies, and other relevant evidence.
Example
“Any explanation for an association between death from
myocardial infarction and use of second generation oral contra-
ceptives must be conjectural. There is no published evidence to
suggest a direct biologic mechanism, and there are no other
epidemiologic studies with relevant results. (…) The increase in
absolute risk is very small and probably applies predominantly to
smokers. Due to the lack of corroborative evidence, and because the
analysis is based on relatively small numbers, more evidence on the
subject is needed. We would not recommend any change in pre-
scribing practice on the strength of these results” [120].
Explanation
The heart of the discussion section is the interpretation of a
study's results. Over-interpretation is common and human: even
when we try hard to give an objective assessment, reviewers often
rightly point out that we went too far in some respects. When
interpreting results, authors should consider the nature of the
study on the discovery to veriﬁcation continuum and potential
sources of bias, including loss to follow-up and non-participation
(see also items 9, 12 and 19). Due consideration should be given
to confounding (item 16a), the results of relevant sensitivity ana-
lyses, and to the issue of multiplicity and subgroup analyses (item
17). Authors should also consider residual confounding due to
unmeasured variables or imprecise measurement of confounders.
For example, socioeconomic status (SES) is associated with many
health outcomes and often differs between groups being compared.
Variables used to measure SES (income, education, or occupation)
are surrogates for other undeﬁned and unmeasured exposures, and
the true confounder will by deﬁnition be measured with error
[208]. Authors should address the real range of uncertainty in es-
timates, which is larger than the statistical uncertainty reﬂected in
conﬁdence intervals. The latter do not take into account other un-
certainties that arise from a study's design, implementation, and
methods of measurement [209].
To guide thinking and conclusions about causality, some may
ﬁnd criteria proposed by Bradford Hill in 1965 helpful [164]. How
strong is the association with the exposure? Did it precede the
onset of disease? Is the association consistently observed in
different studies and settings? Is there supporting evidence from
experimental studies, including laboratory and animal studies?
How speciﬁc is the exposure's putative effect, and is there a dos-
eeresponse relationship? Is the association biologically plausible?
These criteria should not, however, be applied mechanically. For
example, some have argued that relative risks below 2 or 3 should
be ignored [210,211]. This is a reversal of the point by Cornﬁeld et al.
about the strength of large relative risks (see item 12b) [127].
Although a causal effect is more likely with a relative risk of 9, it
does not follow that one below 3 is necessarily spurious. For
instance, the small increase in the risk of childhood leukaemia after
intrauterine irradiation is credible because it concerns an adverse
effect of a medical procedure for which no alternative explanations
are obvious [212]. Moreover, the carcinogenic effects of radiation
are well established. The doubling in the risk of ovarian cancer
associated with eating 2 to 4 eggs per week is not immediately
credible, since dietary habits are associated with a large number of
lifestyle factors as well as SES [213]. In contrast, the credibility of
much debated epidemiologic ﬁndings of a difference in thrombosis
risk between different types of oral contraceptives was greatly
enhanced by the differences in coagulation found in a randomised
cross-over trial [214]. A discussion of the existing external evidence,
from different types of studies, should always be included, but may
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be particularly important for studies reporting small increases in
risk. Further, authors should put their results in context with
similar studies and explain how the new study affects the existing
body of evidence, ideally by referring to a systematic review.
21. Generalisability: Discuss the generalisability (external val-
idity) of the study results.
Example
”How applicable are our estimates to other HIV-1-infected pa-
tients? This is an important question because the accuracy of
prognostic models tends to be lower when applied to data other
than those used to develop them. We addressed this issue by
penalising model complexity, and by choosing models that gener-
alised best to cohorts omitted from the estimation procedure. Our
database included patients from many countries from Europe and
North America, who were treated in different settings. The range of
patients was broad: men and women, from teenagers to elderly
people were included, and the major exposure categories werewell
represented. The severity of immunodeﬁciency at baseline ranged
from not measureable to very severe, and viral load from unde-
tectable to extremely high” [215].
Explanation
Generalisability, also called external validity or applicability, is
the extent to which the results of a study can be applied to other
circumstances [216]. There is no external validity per se; the term is
meaningful only with regard to clearly speciﬁed conditions [217].
Can results be applied to an individual, groups or populations that
differ from those enrolled in the study with regard to age, sex,
ethnicity, severity of disease, and co-morbid conditions? Are the
nature and level of exposures comparable, and the deﬁnitions of
outcomes relevant to another setting or population? Are data that
were collected in longitudinal studies many years ago still relevant
today? Are results from health services research in one country
applicable to health systems in other countries?
The question of whether the results of a study have external
validity is often a matter of judgment that depends on the study
setting, the characteristics of the participants, the exposures
examined, and the outcomes assessed. Thus, it is crucial that au-
thors provide readers with adequate information about the setting
and locations, eligibility criteria, the exposures and how they were
measured, the deﬁnition of outcomes, and the period of recruit-
ment and follow-up. The degree of non-participation and the
proportion of unexposed participants in whom the outcome de-
velops are also relevant. Knowledge of the absolute risk and prev-
alence of the exposure, which will often vary across populations,
are helpful when applying results to other settings and populations
(see Box 7).
2.6. Other information
22. Funding: Give the source of funding and the role of the
funders for the present study and, if applicable, for the
original study on which the present article is based.
Explanation
Some journals require authors to disclose the presence or
absence of ﬁnancial and other conﬂicts of interest [100,218]. Several
investigations show strong associations between the source of
funding and the conclusions of research articles [219e222]. The
conclusions in randomised trials recommended the experimental
drug as the drug of choice much more often (odds ratio 5.3) if the
trial was funded by for-proﬁt organisations, even after adjustment
for the effect size [223]. Other studies document the inﬂuence of
the tobacco and telecommunication industries on the research they
funded [224e227]. There are also examples of undue inﬂuence
when the sponsor is governmental or a non-proﬁt organisation.
Authors or funders may have conﬂicts of interest that inﬂuence
any of the following: the design of the study [228]; choice of ex-
posures [228,229], outcomes [230], statistical methods [231], and
selective publication of outcomes [230] and studies [232]. Conse-
quently, the role of the funders should be described in detail: in
what part of the study they took direct responsibility (e.g., design,
data collection, analysis, drafting of manuscript, decision to pub-
lish) [100]. Other sources of undue inﬂuence include employers
(e.g., university administrators for academic researchers and gov-
ernment supervisors, especially political appointees, for govern-
ment researchers), advisory committees, litigants, and special
interest groups.
3. Concluding remarks
The STROBE Statement aims to provide helpful recommenda-
tions for reporting observational studies in epidemiology. Good
reporting reveals the strengths and weaknesses of a study and fa-
cilitates sound interpretation and application of study results. The
STROBE Statement may also aid in planning observational studies,
and guide peer reviewers and editors in their evaluation of
manuscripts.
We wrote this explanatory article to discuss the importance of
transparent and complete reporting of observational studies, to
explain the rationale behind the different items included in the
checklist, and to give examples from published articles of what we
consider good reporting. We hope that the material presented here
will assist authors and editors in using STROBE.
We stress that STROBE and other recommendations on the
reporting of research [13,233,234] should be seen as evolving
documents that require continual assessment, reﬁnement, and, if
necessary, change [235,236]. For example, the CONSORT Statement
for the reporting of parallel-group randomized trials was ﬁrst
developed in themid 1990s [237]. Since thenmembers of the group
have met regularly to review the need to revise the recommenda-
tions; a revised version appeared in 2001 [233] and a further
version is in development. Similarly, the principles presented in
this article and the STROBE checklist are open to change as new
evidence and critical comments accumulate. The STROBE Web site
(http://www.strobe-statement.org/) provides a forum for discus-
sion and suggestions for improvements of the checklist, this
explanatory document and information about the good reporting of
epidemiological studies.
Several journals ask authors to follow the STROBE Statement in
their instructions to authors (see http://www.strobe-statement.
org/for current list). We invite other journals to adopt the STROBE
Statement and contact us through our Web site to let us know. The
journals publishing the STROBE recommendations provide open
access. The STROBE Statement is therefore widely accessible to the
biomedical community.
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